Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock)
US ˙ NasdaqCM ˙ US00653A1079

Introduction

This page provides a comprehensive analysis of the known insider trading history of Samuel D Isaly. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

See Highest Ranking Insiders
Companies with Reported Insider Positions

The SEC filings indicate Samuel D Isaly has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:XTNT / Xtant Medical Holdings, Inc. 10% Owner 4,679,161
US:KALA / KALA BIO, Inc. 10% Owner 2,692,715
US:PIRS / Pieris Pharmaceuticals, Inc. 10% Owner 49,270
US:LOXO / Loxo Oncology, Inc. Director 941,000
US:SCPH / scPharmaceuticals Inc. 10% Owner 0
US:ASNS / Actelis Networks, Inc. 10% Owner 0
US:RYTM / Rhythm Pharmaceuticals, Inc. 10% Owner 0
US:ROKA / Roka Bioscience, Inc. 10% Owner 0
US:BOLD / Boundless Bio, Inc. 10% Owner 4,129,638
US:GKOS / Glaukos Corporation Director 7,895
US:SYBX / Synlogic, Inc. Director 2,629,992
US:ALPN / Alpine Immune Sciences, Inc. Director, 10% Owner 3,298,516
US:CTIC / CTI BioPharma Corp 10% Owner 0
US:STDY / SteadyMed Ltd. 10% Owner 293,500
US:ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) Director 6,149,377
US:WHWK / Whitehawk Therapeutics, Inc. Director, 10% Owner 4,416,446
US:AGLE / Aeglea BioTherapeutics Inc 10% Owner 1,469,524
US:VRAY / ViewRay Inc. Director, 10% Owner 3,843
US:NBRV / Nabriva Therapeutics Plc Director, 10% Owner 559,754
Director, 10% Owner 0
US:RLYP / Relypsa, Inc. 10% Owner 3,356,400
US:SELB / Selecta Biosciences Inc Director, 10% Owner 0
US:CRVS / Corvus Pharmaceuticals, Inc. Director, 10% Owner 5,379,349
US:NTLA / Intellia Therapeutics, Inc. Director 0
US:OTIC / Otonomy Inc Director 1,850,094
US:DMTX / Dimension Therapeutics, Inc. Director, 10% Owner 0
US:SIEN / Sientra, Inc. 10% Owner 17,100
US:ICPT / Intercept Pharmaceuticals Inc Director 1,120,609
US:DNAI / ProNAi Therapeutics, Inc. Director 0
US:MRTX / Mirati Therapeutics, Inc. 10% Owner 1,267,000
US:XLRN / Acceleron Pharma Inc 0
10% Owner 14,067
US:SUPN / Supernus Pharmaceuticals, Inc. 10% Owner 817,000
US:ANTH / Anthera Pharmaceuticals, Inc. Director 7,462,000
US:AMRN / Amarin Corporation plc - Depositary Receipt (Common Stock) Director 5,700
10% Owner 27,859
US:PCRX / Pacira BioSciences, Inc. 10% Owner 2,446,000
US:CCXI / ChemoCentryx Inc 10% Owner 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Samuel D Isaly. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2017-03-27 ADAP ORBIMED ADVISORS LLC 1,190,476 4.2000 1,190,476 4.2000 4,999,999 364 11.5600 8,761,904 175.24
2016-05-24 ADAP ORBIMED ADVISORS LLC 518,400 10.4800 518,400 10.4800 5,432,832
2016-05-23 ADAP ORBIMED ADVISORS LLC 1,191,600 10.4000 1,191,600 10.4000 12,392,640
2016-05-20 ADAP ORBIMED ADVISORS LLC 2,400 10.0400 2,400 10.0400 24,096

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) Insider Trades
Insider Sales ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) Insider Trades
Insider Purchases AMRN / Amarin Corporation plc - Depositary Receipt (Common Stock) - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

AMRN / Amarin Corporation plc - Depositary Receipt (Common Stock) Insider Trades
Insider Sales AMRN / Amarin Corporation plc - Depositary Receipt (Common Stock) - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
2012-06-19 AMRN ORBIMED ADVISORS LLC 611,200 12.9127 30,560 258.2540 7,892,242 310 6.39 -7,696,964 -97.53
2012-06-19 AMRN ORBIMED ADVISORS LLC 5,900 12.9127 295 258.2540 76,185

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

AMRN / Amarin Corporation plc - Depositary Receipt (Common Stock) Insider Trades
Insider Purchases ANTH / Anthera Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2013-01-30 ANTH ORBIMED ADVISORS LLC 5,700,000 0.6600 712,500 5.2800 3,762,000 170 4.53 -534,375 -14.20
2013-01-25 ANTH ORBIMED ADVISORS LLC 1,762,000 0.6484 220,250 5.1872 1,142,481

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ANTH / Anthera Pharmaceuticals, Inc. Insider Trades
Insider Sales ANTH / Anthera Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
2012-06-29 ANTH ORBIMED ADVISORS LLC 1,283,300 0.7341 160,412 5.8728 942,071 364 0.4631 -867,783 -92.11
2012-03-22 ANTH ORBIMED ADVISORS LLC 1,306,700 2.4031 163,338 19.2248 3,140,131
2012-03-21 ANTH ORBIMED ADVISORS LLC 125,000 2.8665 15,625 22.9320 358,312
2012-03-20 ANTH ORBIMED ADVISORS LLC 116,800 2.8993 14,600 23.1944 338,638

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ANTH / Anthera Pharmaceuticals, Inc. Insider Trades
Insider Purchases BOLD / Boundless Bio, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

BOLD / Boundless Bio, Inc. Insider Trades
Insider Sales BOLD / Boundless Bio, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
2017-09-29 BOLD ORBIMED ADVISORS LLC 672,000 28.2500 672,000 28.2500 18,984,000 730
2017-09-07 BOLD ORBIMED ADVISORS LLC 5,000 22.3500 5,000 22.3500 111,750

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

BOLD / Boundless Bio, Inc. Insider Trades
Insider Purchases CRVS / Corvus Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2016-06-24 CRVS ORBIMED ADVISORS LLC 900 12.9900 900 12.9900 11,691 276 21.3700 7,542 64.51
2016-06-23 CRVS ORBIMED ADVISORS LLC 100 12.9200 100 12.9200 1,292
2016-06-21 CRVS ORBIMED ADVISORS LLC 26,083 12.8700 26,083 12.8700 335,688
2016-06-17 CRVS ORBIMED ADVISORS LLC 12,300 12.4800 12,300 12.4800 153,504
2016-06-16 CRVS ORBIMED ADVISORS LLC 5,000 12.0400 5,000 12.0400 60,200
2016-06-15 CRVS ORBIMED ADVISORS LLC 5,000 11.9400 5,000 11.9400 59,700
2016-06-14 CRVS ORBIMED ADVISORS LLC 10,000 12.7100 10,000 12.7100 127,100
2016-06-10 CRVS ORBIMED ADVISORS LLC 20,000 12.9800 20,000 12.9800 259,600
2016-06-09 CRVS ORBIMED ADVISORS LLC 30,000 12.9500 30,000 12.9500 388,500
2016-05-20 CRVS ORBIMED ADVISORS LLC 4,716 13.0900 4,716 13.0900 61,732
2016-05-19 CRVS ORBIMED ADVISORS LLC 2,539 12.1100 2,539 12.1100 30,747
2016-05-19 CRVS ORBIMED ADVISORS LLC 61 12.7500 61 12.7500 778
2016-05-18 CRVS ORBIMED ADVISORS LLC 4,200 11.5500 4,200 11.5500 48,510

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CRVS / Corvus Pharmaceuticals, Inc. Insider Trades
Insider Sales CRVS / Corvus Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CRVS / Corvus Pharmaceuticals, Inc. Insider Trades
Insider Purchases GKOS / Glaukos Corporation - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

GKOS / Glaukos Corporation Insider Trades
Insider Sales GKOS / Glaukos Corporation - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
2017-09-05 GKOS ORBIMED ADVISORS LLC 173,349 37.9400 173,349 37.9400 6,576,861 78 24.5000 -2,329,810 -35.42
2017-09-05 GKOS ORBIMED ADVISORS LLC 1,651 37.9400 1,651 37.9400 62,639
2017-09-05 GKOS ORBIMED ADVISORS LLC 189,792 39.6300 189,792 39.6300 7,521,457
2017-09-05 GKOS ORBIMED ADVISORS LLC 1,808 39.6300 1,808 39.6300 71,651
2017-09-05 GKOS ORBIMED ADVISORS LLC 58,047 40.7700 58,047 40.7700 2,366,576
2017-09-05 GKOS ORBIMED ADVISORS LLC 553 40.7700 553 40.7700 22,546
2017-09-01 GKOS ORBIMED ADVISORS LLC 109,040 37.7200 109,040 37.7200 4,112,989
2017-09-01 GKOS ORBIMED ADVISORS LLC 1,038 37.7200 1,038 37.7200 39,153
2017-08-31 GKOS ORBIMED ADVISORS LLC 44,498 37.8200 44,498 37.8200 1,682,914
2017-08-31 GKOS ORBIMED ADVISORS LLC 424 37.8200 424 37.8200 16,036
2017-08-17 GKOS ORBIMED ADVISORS LLC 224,780 37.8500 224,780 37.8500 8,507,923
2017-08-17 GKOS ORBIMED ADVISORS LLC 2,140 37.8500 2,140 37.8500 80,999
2017-08-16 GKOS ORBIMED ADVISORS LLC 64,961 38.0100 64,961 38.0100 2,469,168
2017-08-16 GKOS ORBIMED ADVISORS LLC 619 38.0100 619 38.0100 23,528
2017-08-15 GKOS ORBIMED ADVISORS LLC 32,193 38.2900 32,193 38.2900 1,232,670
2017-08-15 GKOS ORBIMED ADVISORS LLC 307 38.2900 307 38.2900 11,755
2017-03-14 GKOS ORBIMED ADVISORS LLC 73,401 44.5400 73,401 44.5400 3,269,281
2017-03-14 GKOS ORBIMED ADVISORS LLC 699 44.5400 699 44.5400 31,133
2017-03-13 GKOS ORBIMED ADVISORS LLC 208,712 45.3000 208,712 45.3000 9,454,654
2017-03-13 GKOS ORBIMED ADVISORS LLC 1,998 45.3000 1,998 45.3000 90,509
2017-03-13 GKOS ORBIMED ADVISORS LLC 693 46.1300 693 46.1300 31,968
2017-03-13 GKOS ORBIMED ADVISORS LLC 7 46.1300 7 46.1300 323
2017-03-10 GKOS ORBIMED ADVISORS LLC 96,113 45.9800 96,113 45.9800 4,419,276
2017-03-10 GKOS ORBIMED ADVISORS LLC 915 45.9800 915 45.9800 42,072
2017-03-03 GKOS ORBIMED ADVISORS LLC 55,246 47.0500 55,246 47.0500 2,599,324
2017-03-03 GKOS ORBIMED ADVISORS LLC 526 47.0500 526 47.0500 24,748
2016-08-12 GKOS ORBIMED ADVISORS LLC 13,967 33.7200 13,967 33.7200 470,967
2016-08-12 GKOS ORBIMED ADVISORS LLC 133 33.7200 133 33.7200 4,485
2016-08-11 GKOS ORBIMED ADVISORS LLC 159,382 33.6300 159,382 33.6300 5,360,017
2016-08-11 GKOS ORBIMED ADVISORS LLC 1,518 33.6300 1,518 33.6300 51,050
2016-08-10 GKOS ORBIMED ADVISORS LLC 116,825 33.7700 116,825 33.7700 3,945,180
2016-08-10 GKOS ORBIMED ADVISORS LLC 1,113 33.7700 1,113 33.7700 37,586
2016-08-03 GKOS ORBIMED ADVISORS LLC 420,990 30.5900 420,990 30.5900 12,878,084
2016-08-03 GKOS ORBIMED ADVISORS LLC 4,010 30.5900 4,010 30.5900 122,666

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

GKOS / Glaukos Corporation Insider Trades
Insider Purchases KALA / KALA BIO, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2018-01-12 KALA ORBIMED ADVISORS LLC 28,446 15.4000 569 770.0000 438,068 63 905 75,972 17.34
2018-01-11 KALA ORBIMED ADVISORS LLC 41,700 13.6500 834 682.5000 569,205
2018-01-10 KALA ORBIMED ADVISORS LLC 170,338 12.8300 3,407 641.5000 2,185,437
2017-07-25 KALA ORBIMED ADVISORS LLC 319,333 15.0000 6,387 750.0000 4,789,995

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

KALA / KALA BIO, Inc. Insider Trades
Insider Sales KALA / KALA BIO, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

KALA / KALA BIO, Inc. Insider Trades
Insider Purchases NBRVF / Nabriva Therapeutics plc - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

NBRVF / Nabriva Therapeutics plc Insider Trades
Insider Sales NBRVF / Nabriva Therapeutics plc - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

NBRVF / Nabriva Therapeutics plc Insider Trades
Insider Purchases NTLA / Intellia Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2016-05-11 NTLA ORBIMED ADVISORS LLC 191,466 18.0000 191,466 18.0000 3,446,388 20 29.57 2,215,262 64.28
2016-05-11 NTLA ORBIMED ADVISORS LLC 58,534 18.0000 58,534 18.0000 1,053,612

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

NTLA / Intellia Therapeutics, Inc. Insider Trades
Insider Sales NTLA / Intellia Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

NTLA / Intellia Therapeutics, Inc. Insider Trades
Insider Purchases PCRX / Pacira BioSciences, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

PCRX / Pacira BioSciences, Inc. Insider Trades
Insider Sales PCRX / Pacira BioSciences, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
2012-03-12 PCRX ORBIMED ADVISORS LLC 62,400 11.0318 62,400 11.0318 688,384 31 9.73 -81,232 -11.80
2012-03-12 PCRX ORBIMED ADVISORS LLC 700 11.0318 700 11.0318 7,722
2012-03-09 PCRX ORBIMED ADVISORS LLC 36,700 11.2456 36,700 11.2456 412,714
2012-03-09 PCRX ORBIMED ADVISORS LLC 300 11.2456 300 11.2456 3,374
2012-02-29 PCRX ORBIMED ADVISORS LLC 3,000 10.8614 3,000 10.8614 32,584
2012-02-28 PCRX ORBIMED ADVISORS LLC 10,000 11.1204 10,000 11.1204 111,204
2012-02-28 PCRX ORBIMED ADVISORS LLC 100 11.1204 100 11.1204 1,112
2012-02-27 PCRX ORBIMED ADVISORS LLC 28,700 11.0472 28,700 11.0472 317,055
2012-02-27 PCRX ORBIMED ADVISORS LLC 300 11.0472 300 11.0472 3,314
2012-02-03 PCRX ORBIMED ADVISORS LLC 49,500 10.7904 49,500 10.7904 534,125
2012-02-03 PCRX ORBIMED ADVISORS LLC 500 10.7904 500 10.7904 5,395
2012-02-02 PCRX ORBIMED ADVISORS LLC 23,100 10.8548 23,100 10.8548 250,746
2012-02-02 PCRX ORBIMED ADVISORS LLC 200 10.8548 200 10.8548 2,171
2012-02-01 PCRX ORBIMED ADVISORS LLC 69,300 11.0058 69,300 11.0058 762,702
2012-02-01 PCRX ORBIMED ADVISORS LLC 700 11.0058 700 11.0058 7,704

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

PCRX / Pacira BioSciences, Inc. Insider Trades
Insider Purchases RNAC / Cartesian Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2016-06-27 SELB ORBIMED ADVISORS LLC 5,189 14.0000 5,189 14.0000 72,646 151 26.3300 63,980 88.07
2016-06-27 SELB ORBIMED ADVISORS LLC 544,811 14.0000 544,811 14.0000 7,627,354

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

RNAC / Cartesian Therapeutics, Inc. Insider Trades
Insider Sales RNAC / Cartesian Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

RNAC / Cartesian Therapeutics, Inc. Insider Trades
Insider Purchases RYTM / Rhythm Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2017-10-10 RYTM ORBIMED ADVISORS LLC 355,000 17.0000 355,000 17.0000 6,035,000 268 35.85 6,691,750 110.88

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

RYTM / Rhythm Pharmaceuticals, Inc. Insider Trades
Insider Sales RYTM / Rhythm Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

RYTM / Rhythm Pharmaceuticals, Inc. Insider Trades
Insider Purchases SCPH / scPharmaceuticals Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2017-11-21 SCPH ORBIMED ADVISORS LLC 833,333 14.0000 833,333 14.0000 11,666,662 112 17.32 2,766,666 23.71

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SCPH / scPharmaceuticals Inc. Insider Trades
Insider Sales SCPH / scPharmaceuticals Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SCPH / scPharmaceuticals Inc. Insider Trades
Insider Purchases SUPN / Supernus Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2012-05-04 SUPN ORBIMED ADVISORS LLC 734,128 5.0000 734,128 5.0000 3,670,640 76 14.86 7,238,502 197.20
2012-05-04 SUPN ORBIMED ADVISORS LLC 274,873 5.0000 274,873 5.0000 1,374,365
2012-05-04 SUPN ORBIMED ADVISORS LLC 90,999 5.0000 90,999 5.0000 454,995

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SUPN / Supernus Pharmaceuticals, Inc. Insider Trades
Insider Sales SUPN / Supernus Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
2013-02-13 SUPN ORBIMED ADVISORS LLC 108,900 7.5757 108,900 7.5757 824,994 71 4.51 -333,854 -40.47
2013-02-13 SUPN ORBIMED ADVISORS LLC 41,100 7.5757 41,100 7.5757 311,361
2013-02-12 SUPN ORBIMED ADVISORS LLC 110,700 7.5218 110,700 7.5218 832,663
2013-02-12 SUPN ORBIMED ADVISORS LLC 41,483 7.5218 41,483 7.5218 312,027
2012-12-18 SUPN ORBIMED ADVISORS LLC 100,000 7.0767 100,000 7.0767 707,670
2012-12-17 SUPN ORBIMED ADVISORS LLC 197,815 6.8479 197,815 6.8479 1,354,617

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SUPN / Supernus Pharmaceuticals, Inc. Insider Trades
Insider Purchases SYBX / Synlogic, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SYBX / Synlogic, Inc. Insider Trades
Insider Sales SYBX / Synlogic, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SYBX / Synlogic, Inc. Insider Trades
Insider Purchases SYRE / Spyre Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2017-02-21 AGLE ORBIMED ADVISORS LLC 7,000 5.3600 280 134.0000 37,520 27 200.75 18,690 49.81
2017-02-17 AGLE ORBIMED ADVISORS LLC 71,800 5.1900 2,872 129.7500 372,642
2017-02-16 AGLE ORBIMED ADVISORS LLC 30,500 5.0400 1,220 126.0000 153,720

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SYRE / Spyre Therapeutics, Inc. Insider Trades
Insider Sales SYRE / Spyre Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SYRE / Spyre Therapeutics, Inc. Insider Trades
Insider Purchases VRAYQ / ViewRay, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2017-01-18 VRAY ORBIMED ADVISORS LLC 327,459 3.0000 327,459 3.0000 982,377 358 10.1200 2,331,508 237.33
2017-01-18 VRAY ORBIMED ADVISORS LLC 3,118 3.0000 3,118 3.0000 9,354
2016-08-22 VRAY ORBIMED ADVISORS LLC 1,127,338 2.9500 1,127,338 2.9500 3,325,647
2016-08-22 VRAY ORBIMED ADVISORS LLC 10,736 2.9500 10,736 2.9500 31,671

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

VRAYQ / ViewRay, Inc. Insider Trades
Insider Sales VRAYQ / ViewRay, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

VRAYQ / ViewRay, Inc. Insider Trades
Insider Purchases WHWK / Whitehawk Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2017-03-15 NONE ORBIMED ADVISORS LLC 762,995 5.0000 50,866 75.0000 3,814,975 299

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

WHWK / Whitehawk Therapeutics, Inc. Insider Trades
Insider Sales WHWK / Whitehawk Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

WHWK / Whitehawk Therapeutics, Inc. Insider Trades
Insider Purchases XTNT / Xtant Medical Holdings, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

XTNT / Xtant Medical Holdings, Inc. Insider Trades
Insider Sales XTNT / Xtant Medical Holdings, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

XTNT / Xtant Medical Holdings, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Samuel D Isaly as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change		 Share
Price		 Tran
Value		 Remaining
Value
2018-01-19 3 XTNT Xtant Medical Holdings, Inc.
Common Stock 		4,679,161
2018-01-19 3 XTNT Xtant Medical Holdings, Inc.
Common Stock 		3,574,391
2018-01-19 3 XTNT Xtant Medical Holdings, Inc.
Common Stock 		4,679,161
2018-01-19 3 XTNT Xtant Medical Holdings, Inc.
Common Stock 		3,574,391
2018-01-19 3 XTNT Xtant Medical Holdings, Inc.
Common Stock 		4,679,161
2018-01-19 3 XTNT Xtant Medical Holdings, Inc.
Common Stock 		3,574,391
2018-01-12 2018-01-12 4 KALA Kala Pharmaceuticals, Inc.
Common Stock 		P - Purchase 28,446 2,692,715 1.07 15.40 438,068 41,467,811
2018-01-12 2018-01-11 4 KALA Kala Pharmaceuticals, Inc.
Common Stock 		P - Purchase 41,700 2,664,269 1.59 13.65 569,205 36,367,272
2018-01-12 2018-01-10 4 KALA Kala Pharmaceuticals, Inc.
Common Stock 		P - Purchase 170,338 2,622,569 6.95 12.83 2,185,437 33,647,560
2018-01-12 3 KALA Kala Pharmaceuticals, Inc.
Common Stock 		4,904,462
2018-01-12 3 KALA Kala Pharmaceuticals, Inc.
Common Stock 		4,904,462
2018-01-12 3 KALA Kala Pharmaceuticals, Inc.
Common Stock 		4,904,462
2018-01-12 3 KALA Kala Pharmaceuticals, Inc.
Common Stock 		4,904,462
2018-01-04 2018-01-03 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 		S - Sale -16,128 49,270 -24.66 7.35 -118,541 362,134
2018-01-04 2018-01-03 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 		S - Sale -1,693,492 5,500,730 -23.54 7.35 -12,447,166 40,430,366
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) 		M - Exercise -47 0 -100.00
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) 		M - Exercise -4,971 0 -100.00
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) 		M - Exercise -99 0 -100.00
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) 		M - Exercise -10,447 0 -100.00
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) 		M - Exercise -97 0 -100.00
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) 		M - Exercise -97 0 -100.00
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) 		M - Exercise -10,216 0 -100.00
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) 		M - Exercise -142 0 -100.00
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) 		M - Exercise -14,858 0 -100.00
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) 		M - Exercise -97 0 -100.00
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) 		M - Exercise -10,182 0 -100.00
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) 		M - Exercise -92 0 -100.00
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) 		M - Exercise -9,642 0 -100.00
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) 		M - Exercise -77 0 -100.00
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) 		M - Exercise -8,097 0 -100.00
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) 		M - Exercise -189 0 -100.00
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) 		M - Exercise -19,811 0 -100.00
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) 		M - Exercise -10,180 0 -100.00
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) 		M - Exercise -83 0 -100.00
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) 		M - Exercise -8,717 0 -100.00
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) 		M - Exercise -63 0 -100.00
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) 		M - Exercise -6,654 0 -100.00
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) 		M - Exercise -50 0 -100.00
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) 		M - Exercise -5,227 0 -100.00
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) 		M - Exercise -259 0 -100.00
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) 		M - Exercise -27,241 0 -100.00
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 		S - Sale -1,392 65,398 -2.08 5.70 -7,934 372,769
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 		S - Sale -146,243 7,194,222 -1.99 5.70 -833,585 41,007,065
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 		M - Exercise 47 66,790 0.07 5.64 265 376,696
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 		M - Exercise 4,971 7,340,465 0.07 5.64 28,036 41,400,223
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 		M - Exercise 99 66,743 0.15 2.32 230 154,844
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 		M - Exercise 10,447 7,335,494 0.14 2.32 24,237 17,018,346
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 		M - Exercise 97 66,644 0.15 2.01 195 133,954
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 		M - Exercise 10,216 7,325,047 0.14 2.01 20,534 14,723,344
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 		M - Exercise 142 66,547 0.21 2.01 285 133,759
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 		M - Exercise 14,858 7,314,831 0.20 2.01 29,865 14,702,810
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 		M - Exercise 97 66,405 0.15 1.64 159 108,904
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 		M - Exercise 10,182 7,299,973 0.14 1.64 16,698 11,971,956
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 		M - Exercise 92 66,308 0.14 1.73 159 114,713
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 		M - Exercise 9,642 7,289,791 0.13 1.73 16,681 12,611,338
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 		M - Exercise 77 66,216 0.12 2.05 158 135,743
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 		M - Exercise 8,097 7,280,149 0.11 2.05 16,599 14,924,305
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 		M - Exercise 189 66,139 0.29 1.59 301 105,161
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 		M - Exercise 19,811 7,272,052 0.27 1.59 31,499 11,562,563
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 		M - Exercise 97 65,950 0.15 1.62 157 106,839
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 		M - Exercise 10,180 7,252,241 0.14 1.62 16,492 11,748,630
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 		M - Exercise 83 65,853 0.13 1.94 161 127,755
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 		M - Exercise 8,717 7,242,061 0.12 1.94 16,911 14,049,598
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 		M - Exercise 63 65,770 0.10 2.62 165 172,317
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 		M - Exercise 6,654 7,233,344 0.09 2.62 17,433 18,951,361
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 		M - Exercise 50 65,707 0.08 3.00 150 197,121
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 		M - Exercise 5,227 7,226,690 0.07 3.00 15,681 21,680,070
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 		M - Exercise 259 65,657 0.40 2.00 518 131,314
2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 		M - Exercise 27,241 7,221,463 0.38 2.00 54,482 14,442,926
2017-12-12 2017-12-08 4 LOXO Loxo Oncology, Inc.
Common Stock 		S - Sale -250,000 941,000 -20.99 82.50 -20,625,000 77,632,500
2017-11-27 2017-11-22 4 LOXO Loxo Oncology, Inc.
Common Stock 		S - Sale -267,000 1,191,000 -18.31 75.00 -20,025,000 89,325,000
2017-11-21 2017-11-21 4 SCPH scPharmaceuticals Inc.
Series B Preferred Stock 		C - Conversion -18,500,000 0 -100.00
2017-11-21 2017-11-21 4 SCPH scPharmaceuticals Inc.
Common Stock 		P - Purchase 833,333 3,409,865 32.34 14.00 11,666,662 47,738,110
2017-11-21 2017-11-21 4 SCPH scPharmaceuticals Inc.
Common Stock 		C - Conversion 2,576,532 2,576,532
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Series D Convertible Preferred Stock 		C - Conversion -2,232,014 0 -100.00
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Series C Convertible Preferred Stock 		C - Conversion -229,412 0 -100.00
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Series B Convertible Preferred Stock 		C - Conversion -736,648 0 -100.00
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Series A-2 Convertible Preferred Stock 		C - Conversion -704,846 0 -100.00
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Series A-1 Convertible Preferred Stock 		C - Conversion -66,667 0 -100.00
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock 		C - Conversion 500,000 1,868,966 36.52 10.00 5,000,000 18,689,660
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock 		C - Conversion 653,974 1,368,966 91.47
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock 		C - Conversion 114,320 714,992 19.03
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock 		C - Conversion 328,909 600,672 121.03
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock 		C - Conversion 252,230 271,763 1,291.30
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock 		C - Conversion 19,533 19,533
2017-11-20 2017-11-16 4 LOXO Loxo Oncology, Inc.
Common Stock 		S - Sale -8,377 1,458,000 -0.57 76.23 -638,579 111,143,340
2017-11-20 2017-11-16 4 LOXO Loxo Oncology, Inc.
Common Stock 		S - Sale -71,598 1,466,377 -4.66 75.37 -5,396,341 110,520,834
2017-11-20 2017-11-16 4 LOXO Loxo Oncology, Inc.
Common Stock 		S - Sale -100,045 1,537,975 -6.11 74.49 -7,452,352 114,563,758
2017-11-20 2017-11-16 4 LOXO Loxo Oncology, Inc.
Common Stock 		S - Sale -43,300 1,638,020 -2.58 73.48 -3,181,684 120,361,710
2017-11-20 2017-11-16 4 LOXO Loxo Oncology, Inc.
Common Stock 		S - Sale -46,680 1,681,320 -2.70 72.46 -3,382,433 121,828,447
2017-10-10 2017-10-10 4 RYTM RHYTHM PHARMACEUTICALS, INC.
Series A Convertible Preferred Stock 		C - Conversion -2,546,295 0 -100.00
2017-10-10 2017-10-10 4 RYTM RHYTHM PHARMACEUTICALS, INC.
Common Stock 		P - Purchase 355,000 2,901,295 13.94 17.00 6,035,000 49,322,015
2017-10-10 2017-10-10 4 RYTM RHYTHM PHARMACEUTICALS, INC.
Common Stock 		C - Conversion 2,546,295 2,546,295
2017-10-05 2017-10-03 4 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share 		S - Sale -1,899 0 -100.00 0.68 -1,291
2017-10-05 2017-10-03 4 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share 		S - Sale -199,718 0 -100.00 0.68 -135,808
2017-10-02 2017-09-29 4 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share 		S - Sale -888 1,899 -31.86 0.74 -657 1,405
2017-10-02 2017-09-29 4 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share 		S - Sale -93,246 199,718 -31.83 0.74 -69,002 147,791
2017-10-02 2017-09-28 4 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share 		S - Sale -3,592 2,787 -56.31 0.72 -2,586 2,007
2017-10-02 2017-09-28 4 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share 		S - Sale -376,950 292,964 -56.27 0.72 -271,404 210,934
2017-09-29 2017-09-29 4 BOLD Audentes Therapeutics, Inc.
Common Stock 		S - Sale -672,000 4,129,638 -14.00 28.25 -18,984,000 116,662,274
2017-09-28 2017-09-27 4 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share 		S - Sale -498 6,379 -7.24 0.92 -458 5,869
2017-09-28 2017-09-27 4 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share 		S - Sale -52,301 669,914 -7.24 0.92 -48,117 616,321
2017-09-28 2017-09-26 4 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share 		S - Sale -706 6,877 -9.31 1.03 -727 7,083
2017-09-28 2017-09-26 4 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share 		S - Sale -74,096 722,215 -9.30 1.03 -76,319 743,881
2017-09-11 2017-09-07 4 BOLD Audentes Therapeutics, Inc.
Stock Option (right to buy) 		X - Other -5,000 0 -100.00
2017-09-11 2017-09-07 4 BOLD Audentes Therapeutics, Inc.
Common Stock 		S - Sale -5,000 4,801,638 -0.10 22.35 -111,750 107,316,609
2017-09-11 2017-09-07 4 BOLD Audentes Therapeutics, Inc.
Common Stock 		X - Other 5,000 4,806,638 0.10 15.03 75,150 72,243,769
2017-09-05 2017-09-05 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share 		S - Sale -553 7,895 -6.55 40.77 -22,546 321,879
2017-09-05 2017-09-05 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share 		S - Sale -58,047 828,605 -6.55 40.77 -2,366,576 33,782,226
2017-09-05 2017-09-05 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share 		S - Sale -1,808 8,448 -17.63 39.63 -71,651 334,794
2017-09-05 2017-09-05 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share 		S - Sale -189,792 886,652 -17.63 39.63 -7,521,457 35,138,019
2017-09-05 2017-09-05 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share 		S - Sale -1,651 10,256 -13.87 37.94 -62,639 389,113
2017-09-05 2017-09-05 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share 		S - Sale -173,349 1,076,444 -13.87 37.94 -6,576,861 40,840,285
2017-09-05 2017-09-01 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share 		S - Sale -1,038 11,907 -8.02 37.72 -39,153 449,132
2017-09-05 2017-09-01 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share 		S - Sale -109,040 1,249,793 -8.02 37.72 -4,112,989 47,142,192
2017-09-05 2017-08-31 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share 		S - Sale -424 12,945 -3.17 37.82 -16,036 489,580
2017-09-05 2017-08-31 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share 		S - Sale -44,498 1,358,833 -3.17 37.82 -1,682,914 51,391,064
2017-08-30 3 SYBX SYNLOGIC, INC.
Common Stock 		2,629,992
2017-08-30 3 SYBX SYNLOGIC, INC.
Common Stock 		2,629,992
2017-08-30 3 SYBX SYNLOGIC, INC.
Common Stock 		2,629,992
2017-08-30 3 SYBX SYNLOGIC, INC.
Common Stock 		2,629,992
2017-08-25 2017-08-24 4 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share 		S - Sale -125 7,583 -1.62 1.50 -188 11,374
2017-08-25 2017-08-24 4 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share 		S - Sale -13,075 796,311 -1.62 1.50 -19,612 1,194,466
2017-08-25 2017-08-23 4 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share 		S - Sale -10 7,708 -0.13 1.50 -15 11,562
2017-08-25 2017-08-23 4 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share 		S - Sale -1,090 809,386 -0.13 1.50 -1,635 1,214,079
2017-08-22 2017-08-22 4 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share 		S - Sale -52 7,718 -0.67 1.52 -79 11,731
2017-08-22 2017-08-22 4 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share 		S - Sale -5,448 810,476 -0.67 1.52 -8,281 1,231,924
2017-08-22 2017-08-21 4 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share 		S - Sale -28 7,770 -0.36 1.49 -42 11,577
2017-08-22 2017-08-21 4 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share 		S - Sale -2,952 815,924 -0.36 1.49 -4,398 1,215,727
2017-08-22 2017-08-18 4 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share 		S - Sale -630 7,798 -7.48 1.52 -958 11,853
2017-08-22 2017-08-18 4 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share 		S - Sale -66,166 818,876 -7.48 1.52 -100,572 1,244,692
2017-08-17 2017-08-17 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share 		S - Sale -2,140 13,369 -13.80 37.85 -80,999 506,017
2017-08-17 2017-08-17 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share 		S - Sale -224,780 1,403,331 -13.81 37.85 -8,507,923 53,116,078
2017-08-17 2017-08-16 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share 		S - Sale -619 15,509 -3.84 38.01 -23,528 589,497
2017-08-17 2017-08-16 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share 		S - Sale -64,961 1,628,111 -3.84 38.01 -2,469,168 61,884,499
2017-08-17 2017-08-15 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share 		S - Sale -307 16,128 -1.87 38.29 -11,755 617,541
2017-08-17 2017-08-15 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share 		S - Sale -32,193 1,693,072 -1.87 38.29 -1,232,670 64,827,727
2017-07-27 2017-07-25 4 KALA Kala Pharmaceuticals, Inc.
Series C Preferred Stock 		C - Conversion -10,707,985 0 -100.00
2017-07-27 2017-07-25 4 KALA Kala Pharmaceuticals, Inc.
Common Stock 		P - Purchase 319,333 2,375,279 15.53 15.00 4,789,995 35,629,185
2017-07-27 2017-07-25 4 KALA Kala Pharmaceuticals, Inc.
Common Stock 		C - Conversion 2,055,946 2,055,946
2017-07-26 2017-07-24 4 ALPN ALPINE IMMUNE SCIENCES, INC.
Common Stock 		A - Award 3,298,516 3,298,516
2017-06-15 2017-06-13 4 CTIC CTI BIOPHARMA CORP
Series N-3 Preferred Stock 		C - Conversion -7,500 0 -100.00
2017-06-15 2017-06-13 4 CTIC CTI BIOPHARMA CORP
Common Stock 		C - Conversion 5,000,000 5,000,000
2017-04-27 2017-04-25 4 STDY SteadyMed Ltd.
Warrants to Purchase Ordinary Shares 		P - Purchase 293,500 293,500 0.12 36,688 36,688
2017-04-27 2017-04-25 4 STDY SteadyMed Ltd.
Warrants to Purchase Ordinary Shares 		P - Purchase 293,500 293,500 0.12 36,688 36,688
2017-04-27 2017-04-25 4 STDY SteadyMed Ltd.
Ordinary Shares, nominal value NIS 0.01 per share 		P - Purchase 587,000 2,123,098 38.21 5.90 3,463,300 12,526,278
2017-04-27 2017-04-25 4 STDY SteadyMed Ltd.
Ordinary Shares, nominal value NIS 0.01 per share 		P - Purchase 587,000 2,123,098 38.21 5.90 3,463,300 12,526,278
2017-03-28 2017-03-27 4 ADAP Adaptimmune Therapeutics PLC
American Depositary Shares representing Ordinary Shares 		P - Purchase 1,190,476 6,149,377 24.01 4.20 4,999,999 25,827,383
2017-03-17 2017-03-15 4 NONE Aerpio Pharmaceuticals, Inc.
Common Stock 		P - Purchase 762,995 4,416,446 20.88 5.00 3,814,975 22,082,230
2017-03-17 3 NONE Aerpio Pharmaceuticals, Inc.
Common Stock 		7,306,902
2017-03-17 3 NONE Aerpio Pharmaceuticals, Inc.
Common Stock 		7,306,902
2017-03-17 3 NONE Aerpio Pharmaceuticals, Inc.
Common Stock 		7,306,902
2017-03-17 3 NONE Aerpio Pharmaceuticals, Inc.
Common Stock 		7,306,902
2017-03-14 2017-03-14 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share 		S - Sale -699 16,435 -4.08 44.54 -31,133 732,015
2017-03-14 2017-03-14 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share 		S - Sale -73,401 1,725,265 -4.08 44.54 -3,269,281 76,843,303
2017-03-14 2017-03-13 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share 		S - Sale -7 17,134 -0.04 46.13 -323 790,391
2017-03-14 2017-03-13 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share 		S - Sale -693 1,798,666 -0.04 46.13 -31,968 82,972,463
2017-03-14 2017-03-13 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share 		S - Sale -1,998 17,141 -10.44 45.30 -90,509 776,487
2017-03-14 2017-03-13 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share 		S - Sale -208,712 1,799,359 -10.39 45.30 -9,454,654 81,510,963
2017-03-14 2017-03-10 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share 		S - Sale -915 19,129 -4.56 45.98 -42,072 879,551
2017-03-14 2017-03-10 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share 		S - Sale -96,113 2,008,071 -4.57 45.98 -4,419,276 92,331,105
2017-03-07 2017-03-03 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share 		S - Sale -526 20,044 -2.56 47.05 -24,748 943,070
2017-03-07 2017-03-03 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share 		S - Sale -55,246 2,104,184 -2.56 47.05 -2,599,324 99,001,857
2017-02-21 2017-02-21 4 AGLE Aeglea BioTherapeutics, Inc.
Common Stock 		P - Purchase 7,000 1,469,524 0.48 5.36 37,520 7,876,649
2017-02-21 2017-02-17 4 AGLE Aeglea BioTherapeutics, Inc.
Common Stock 		P - Purchase 71,800 1,462,524 5.16 5.19 372,642 7,590,500
2017-02-21 2017-02-16 4 AGLE Aeglea BioTherapeutics, Inc.
Common Stock 		P - Purchase 30,500 1,390,724 2.24 5.04 153,720 7,009,249
2017-01-20 2017-01-18 4 VRAY ViewRay, Inc.
Warrants to purchase common stock 		P - Purchase 623 3,843 19.35 0.12 78 480
2017-01-20 2017-01-18 4 VRAY ViewRay, Inc.
Warrants to purchase common stock 		P - Purchase 65,491 403,692 19.36 0.12 8,186 50,462
2017-01-20 2017-01-18 4 VRAY ViewRay, Inc.
Common Stock, par value $0.01 per share 		P - Purchase 3,118 89,225 3.62 3.00 9,354 267,675
2017-01-20 2017-01-18 4 VRAY ViewRay, Inc.
Common Stock, par value $0.01 per share 		P - Purchase 327,459 9,369,342 3.62 3.00 982,377 28,108,026
2016-12-30 3 NBRV Nabriva Therapeutics AG
Common Shares 		559,754
2016-12-30 3 NBRV Nabriva Therapeutics AG
Common Shares 		616,126
2016-12-30 3 NBRV Nabriva Therapeutics AG
Common Shares 		559,754
2016-12-30 3 NBRV Nabriva Therapeutics AG
Common Shares 		616,126
2016-12-30 3 NBRV Nabriva Therapeutics AG
Common Shares 		559,754
2016-12-30 3 NBRV Nabriva Therapeutics AG
Common Shares 		616,126
2016-12-30 3 NBRV Nabriva Therapeutics AG
Common Shares 		559,754
2016-12-30 3 NBRV Nabriva Therapeutics AG
Common Shares 		616,126
2016-12-01 2016-11-29 4 RBM RESPONSE BIOMEDICAL CORP
Common Stock 		J - Other -2,149,902 0 -100.00
2016-12-01 2016-11-29 4 RBM RESPONSE BIOMEDICAL CORP
Common Stock 		J - Other -34,291 0 -100.00
2016-12-01 2016-11-29 4 RBM RESPONSE BIOMEDICAL CORP
Common Stock 		J - Other -3,604,266 0 -100.00
2016-09-23 2016-09-21 4 ROKA Roka BioScience, Inc.
Warrants 		P - Purchase 53,909 53,909
2016-09-23 2016-09-21 4 ROKA Roka BioScience, Inc.
Warrants 		P - Purchase 5,660,377 5,660,377
2016-09-23 2016-09-21 4 ROKA Roka BioScience, Inc.
Series A Convertible Preferred Stock 		P - Purchase 38 38
2016-09-23 2016-09-21 4 ROKA Roka BioScience, Inc.
Series A Convertible Preferred Stock 		P - Purchase 3,962 3,962
2016-08-24 2016-08-22 4 VRAY ViewRay, Inc.
Warrants to purchase common stock 		P - Purchase 3,220 3,220 0.12 402 402
2016-08-24 2016-08-22 4 VRAY ViewRay, Inc.
Warrants to purchase common stock 		P - Purchase 338,201 338,201 0.12 42,275 42,275
2016-08-24 2016-08-22 4 VRAY ViewRay, Inc.
Common Stock, par value $0.01 per share 		P - Purchase 10,736 86,107 14.24 2.95 31,671 254,016
2016-08-24 2016-08-22 4 VRAY ViewRay, Inc.
Common Stock, par value $0.01 per share 		P - Purchase 1,127,338 9,041,883 14.24 2.95 3,325,647 26,673,555
2016-08-12 2016-08-10 4 LOXO Loxo Oncology, Inc.
Common Stock 		S - Sale -447,857 1,728,000 -20.58 26.96 -12,074,225 46,586,880
2016-08-12 2016-08-12 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share 		S - Sale -133 20,570 -0.64 33.72 -4,485 693,620
2016-08-12 2016-08-12 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share 		S - Sale -13,967 2,159,430 -0.64 33.72 -470,967 72,815,980
2016-08-12 2016-08-11 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share 		S - Sale -1,518 20,703 -6.83 33.63 -51,050 696,242
2016-08-12 2016-08-11 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share 		S - Sale -159,382 2,173,397 -6.83 33.63 -5,360,017 73,091,341
2016-08-12 2016-08-10 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share 		S - Sale -1,113 22,221 -4.77 33.77 -37,586 750,403
2016-08-12 2016-08-10 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share 		S - Sale -116,825 2,332,779 -4.77 33.77 -3,945,180 78,777,947
2016-08-12 3 STDY SteadyMed Ltd.
Ordinary Shares 		4,608,294
2016-08-12 3 STDY SteadyMed Ltd.
Ordinary Shares 		4,608,294
2016-08-12 3 STDY SteadyMed Ltd.
Ordinary Shares 		4,608,294
2016-08-12 3 STDY SteadyMed Ltd.
Ordinary Shares 		4,608,294
2016-08-12 3 STDY SteadyMed Ltd.
Ordinary Shares 		4,608,294
2016-08-12 3 STDY SteadyMed Ltd.
Ordinary Shares 		4,608,294
2016-08-12 3 STDY SteadyMed Ltd.
Ordinary Shares 		4,608,294
2016-08-12 3 STDY SteadyMed Ltd.
Ordinary Shares 		4,608,294
2016-08-12 3 STDY SteadyMed Ltd.
Ordinary Shares 		4,608,294
2016-08-12 3 STDY SteadyMed Ltd.
Ordinary Shares 		4,608,294
2016-08-12 3 STDY SteadyMed Ltd.
Ordinary Shares 		4,608,294
2016-08-12 3 STDY SteadyMed Ltd.
Ordinary Shares 		4,608,294
2016-08-05 2016-08-03 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share 		S - Sale -4,010 23,334 -14.67 30.59 -122,666 713,787
2016-08-05 2016-08-03 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share 		S - Sale -420,990 2,449,604 -14.67 30.59 -12,878,084 74,933,386
2016-07-26 2016-07-25 4 RLYP Relypsa Inc
Common Stock 		S - Sale -343,600 3,356,400 -9.29 31.98 -10,988,328 107,337,672
2016-07-26 2016-07-22 4 RLYP Relypsa Inc
Common Stock 		S - Sale -3,700,000 3,700,000 -50.00 32.00 -118,400,000 118,400,000
2016-07-19 3 BOLD Audentes Therapeutics, Inc.
Common Stock 		448,476
2016-07-19 3 BOLD Audentes Therapeutics, Inc.
Common Stock 		448,476
2016-07-19 3 BOLD Audentes Therapeutics, Inc.
Common Stock 		448,476
2016-07-19 3 BOLD Audentes Therapeutics, Inc.
Common Stock 		448,476
2016-06-29 2016-06-27 4 SELB SELECTA BIOSCIENCES INC
Series E Convertible Preferred Stock 		C - Conversion -456,870 0 -100.00
2016-06-29 2016-06-27 4 SELB SELECTA BIOSCIENCES INC
Series E Convertible Preferred Stock 		C - Conversion -4,351 0 -100.00
2016-06-29 2016-06-27 4 SELB SELECTA BIOSCIENCES INC
Series D Convertible Preferred Stock 		C - Conversion -77,697 0 -100.00
2016-06-29 2016-06-27 4 SELB SELECTA BIOSCIENCES INC
Series D Convertible Preferred Stock 		C - Conversion -739 0 -100.00
2016-06-29 2016-06-27 4 SELB SELECTA BIOSCIENCES INC
Series C Convertible Preferred Stock 		C - Conversion -380,986 0 -100.00
2016-06-29 2016-06-27 4 SELB SELECTA BIOSCIENCES INC
Series C Convertible Preferred Stock 		C - Conversion -3,628 0 -100.00
2016-06-29 2016-06-27 4 SELB SELECTA BIOSCIENCES INC
Common Stock 		P - Purchase 544,811 1,825,415 42.54 14.00 7,627,354 25,555,810
2016-06-29 2016-06-27 4 SELB SELECTA BIOSCIENCES INC
Common Stock 		P - Purchase 5,189 17,382 42.56 14.00 72,646 243,348
2016-06-29 2016-06-27 4 SELB SELECTA BIOSCIENCES INC
Common Stock 		C - Conversion 1,166,884 1,280,604 1,026.10
2016-06-29 2016-06-27 4 SELB SELECTA BIOSCIENCES INC
Common Stock 		C - Conversion 11,111 12,193 1,026.89
2016-06-29 2016-06-27 4 SELB SELECTA BIOSCIENCES INC
Series E Convertible Preferred Stock 		C - Conversion -456,870 0 -100.00
2016-06-29 2016-06-27 4 SELB SELECTA BIOSCIENCES INC
Series E Convertible Preferred Stock 		C - Conversion -4,351 0 -100.00
2016-06-29 2016-06-27 4 SELB SELECTA BIOSCIENCES INC
Series D Convertible Preferred Stock 		C - Conversion -77,697 0 -100.00
2016-06-29 2016-06-27 4 SELB SELECTA BIOSCIENCES INC
Series D Convertible Preferred Stock 		C - Conversion -739 0 -100.00
2016-06-29 2016-06-27 4 SELB SELECTA BIOSCIENCES INC
Series C Convertible Preferred Stock 		C - Conversion -380,986 0 -100.00
2016-06-29 2016-06-27 4 SELB SELECTA BIOSCIENCES INC
Series C Convertible Preferred Stock 		C - Conversion -3,628 0 -100.00
2016-06-29 2016-06-27 4 SELB SELECTA BIOSCIENCES INC
Common Stock 		P - Purchase 544,811 1,825,415 42.54 14.00 7,627,354 25,555,810
2016-06-29 2016-06-27 4 SELB SELECTA BIOSCIENCES INC
Common Stock 		P - Purchase 5,189 17,382 42.56 14.00 72,646 243,348
2016-06-29 2016-06-27 4 SELB SELECTA BIOSCIENCES INC
Common Stock 		C - Conversion 1,166,884 1,280,604 1,026.10
2016-06-29 2016-06-27 4 SELB SELECTA BIOSCIENCES INC
Common Stock 		C - Conversion 11,111 12,193 1,026.89
2016-06-27 2016-06-24 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value 		P - Purchase 900 5,379,349 0.02 12.99 11,691 69,877,744
2016-06-27 2016-06-23 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value 		P - Purchase 100 5,378,449 0.00 12.92 1,292 69,489,561
2016-06-21 2016-06-21 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value 		P - Purchase 26,083 5,378,349 0.49 12.87 335,688 69,219,352
2016-06-21 2016-06-17 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value 		P - Purchase 12,300 5,352,266 0.23 12.48 153,504 66,796,280
2016-06-21 3 SELB SELECTA BIOSCIENCES INC
Common Stock 		115,884
2016-06-21 3 SELB SELECTA BIOSCIENCES INC
Common Stock 		228,522
2016-06-21 3 SELB SELECTA BIOSCIENCES INC
Common Stock 		115,884
2016-06-21 3 SELB SELECTA BIOSCIENCES INC
Common Stock 		228,522
2016-06-21 3 SELB SELECTA BIOSCIENCES INC
Common Stock 		115,884
2016-06-21 3 SELB SELECTA BIOSCIENCES INC
Common Stock 		228,522
2016-06-21 3 SELB SELECTA BIOSCIENCES INC
Common Stock 		115,884
2016-06-21 3 SELB SELECTA BIOSCIENCES INC
Common Stock 		228,522
2016-06-20 2016-06-16 4 RBM RESPONSE BIOMEDICAL CORP
Common Stock 		P - Purchase 331,225 2,149,902 18.21 0.56 185,486 1,203,945
2016-06-20 2016-06-16 4 RBM RESPONSE BIOMEDICAL CORP
Common Stock 		P - Purchase 5,294 34,291 18.26 0.56 2,965 19,203
2016-06-20 2016-06-16 4 RBM RESPONSE BIOMEDICAL CORP
Common Stock 		P - Purchase 556,339 3,604,266 18.25 0.56 311,550 2,018,389
2016-06-16 2016-06-16 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value 		P - Purchase 5,000 5,339,966 0.09 12.04 60,200 64,293,191
2016-06-16 2016-06-15 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value 		P - Purchase 5,000 5,334,966 0.09 11.94 59,700 63,699,494
2016-06-16 2016-06-14 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value 		P - Purchase 10,000 5,329,966 0.19 12.71 127,100 67,743,868
2016-06-13 2016-06-10 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value 		P - Purchase 20,000 5,319,966 0.38 12.98 259,600 69,053,159
2016-06-13 2016-06-09 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value 		P - Purchase 30,000 5,299,966 0.57 12.95 388,500 68,634,560
2016-05-25 2016-05-24 4 ADAP Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of GBP0.001 per share 		P - Purchase 518,400 29,753,404 1.77 10.48 5,432,832 311,815,674
2016-05-25 2016-05-23 4 ADAP Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of GBP0.001 per share 		P - Purchase 1,191,600 29,235,004 4.25 10.40 12,392,640 304,044,042
2016-05-25 2016-05-20 4 ADAP Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of GBP0.001 per share 		P - Purchase 2,400 28,043,404 0.01 10.04 24,096 281,555,776
2016-05-24 2016-05-20 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value 		P - Purchase 4,716 5,269,966 0.09 13.09 61,732 68,983,855
2016-05-20 2016-05-19 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value 		P - Purchase 61 5,265,250 0.00 12.75 778 67,131,938
2016-05-20 2016-05-19 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value 		P - Purchase 2,539 5,265,189 0.05 12.11 30,747 63,761,439
2016-05-20 2016-05-18 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value 		P - Purchase 4,200 5,262,650 0.08 11.55 48,510 60,783,608
2016-05-13 2016-05-11 4 NTLA Intellia Therapeutics, Inc.
Series B Preferred Stock 		C - Conversion -873,475 0 -100.00
2016-05-13 2016-05-11 4 NTLA Intellia Therapeutics, Inc.
Series B Preferred Stock 		C - Conversion -2,857,143 0 -100.00
2016-05-13 2016-05-11 4 NTLA Intellia Therapeutics, Inc.
Common Stock 		P - Purchase 58,534 2,662,180 2.25 18.00 1,053,612 47,919,240
2016-05-13 2016-05-11 4 NTLA Intellia Therapeutics, Inc.
Common Stock 		P - Purchase 191,466 2,603,646 7.94 18.00 3,446,388 46,865,628
2016-05-13 2016-05-11 4 NTLA Intellia Therapeutics, Inc.
Common Stock 		C - Conversion 564,780 2,412,180 30.57
2016-05-13 2016-05-11 4 NTLA Intellia Therapeutics, Inc.
Common Stock 		C - Conversion 1,847,400 1,847,400
2016-04-19 3 AGLE Aeglea BioTherapeutics, Inc.
Common Stock 		2,720,448
2016-04-19 3 AGLE Aeglea BioTherapeutics, Inc.
Common Stock 		2,720,448
2016-04-19 3 AGLE Aeglea BioTherapeutics, Inc.
Common Stock 		2,720,448
2016-04-19 3 AGLE Aeglea BioTherapeutics, Inc.
Common Stock 		2,720,448
2016-03-30 3 VRAY ViewRay, Inc.
Common Stock 		15,904,461
2016-03-30 3 VRAY ViewRay, Inc.
Common Stock 		8,065,287
2016-03-30 3 VRAY ViewRay, Inc.
Common Stock 		15,904,461
2016-03-30 3 VRAY ViewRay, Inc.
Common Stock 		8,065,287
2016-03-30 3 VRAY ViewRay, Inc.
Common Stock 		15,904,461
2016-03-30 3 VRAY ViewRay, Inc.
Common Stock 		8,065,287
2016-03-30 3 VRAY ViewRay, Inc.
Common Stock 		15,904,461
2016-03-30 3 VRAY ViewRay, Inc.
Common Stock 		8,065,287
2016-01-04 3 ADAP Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of GBP0.001 per share 		53,449,304
2016-01-04 3 ADAP Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of GBP0.001 per share 		30,673,708
2016-01-04 3 ADAP Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of GBP0.001 per share 		53,449,304
2016-01-04 3 ADAP Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of GBP0.001 per share 		30,673,708
2016-01-04 3 ADAP Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of GBP0.001 per share 		53,449,304
2016-01-04 3 ADAP Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of GBP0.001 per share 		30,673,708
2016-01-04 3 ADAP Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of GBP0.001 per share 		53,449,304
2016-01-04 3 ADAP Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of GBP0.001 per share 		30,673,708
2015-12-23 2015-12-23 4 RLYP Relypsa Inc
Common Stock 		S - Sale -52,058 7,400,000 -0.70 27.54 -1,433,677 203,796,000
2015-12-23 2015-12-23 4 RLYP Relypsa Inc
Common Stock 		S - Sale -47,942 7,452,058 -0.64 26.78 -1,283,887 199,566,113
2015-12-23 2015-12-22 4 RLYP Relypsa Inc
Common Stock 		S - Sale -38,630 7,500,000 -0.51 27.02 -1,043,783 202,650,000
2015-12-23 2015-12-22 4 RLYP Relypsa Inc
Common Stock 		S - Sale -111,370 7,538,630 -1.46 26.39 -2,939,054 198,944,446
2015-12-23 2015-12-21 4 RLYP Relypsa Inc
Common Stock 		S - Sale -14,171 7,650,000 -0.18 28.39 -402,315 217,183,500
2015-12-23 2015-12-21 4 RLYP Relypsa Inc
Common Stock 		S - Sale -235,829 7,664,171 -2.99 27.50 -6,485,298 210,764,702
2015-11-30 2015-11-30 4 OTIC Otonomy, Inc.
Common Stock 		S - Sale -590 1,850,094 -0.03 29.22 -17,240 54,059,747
2015-11-30 2015-11-30 4 OTIC Otonomy, Inc.
Common Stock 		S - Sale -2,716 1,850,684 -0.15 28.64 -77,786 53,003,590
2015-11-30 2015-11-27 4 OTIC Otonomy, Inc.
Common Stock 		S - Sale -29,000 1,853,400 -1.54 28.97 -840,130 53,692,998
2015-11-30 2015-11-25 4 OTIC Otonomy, Inc.
Common Stock 		S - Sale -34,800 1,882,400 -1.82 28.91 -1,006,068 54,420,184
2015-11-24 2015-11-24 4 OTIC Otonomy, Inc.
Common Stock 		S - Sale -36,100 1,917,200 -1.85 28.75 -1,037,875 55,119,500
2015-11-24 2015-11-23 4 OTIC Otonomy, Inc.
Common Stock 		S - Sale -80,800 1,953,300 -3.97 28.45 -2,298,760 55,571,385
2015-11-24 2015-11-20 4 OTIC Otonomy, Inc.
Common Stock 		S - Sale -83,900 2,034,100 -3.96 28.59 -2,398,701 58,154,919
2015-11-19 2015-11-19 4 OTIC Otonomy, Inc.
Common Stock 		S - Sale -127,300 2,118,000 -5.67 28.60 -3,640,780 60,574,800
2015-11-19 2015-11-17 4 OTIC Otonomy, Inc.
Common Stock 		S - Sale -200 2,245,300 -0.01 29.09 -5,818 65,315,777
2015-11-19 2015-11-17 4 OTIC Otonomy, Inc.
Common Stock 		S - Sale -10,898 2,245,500 -0.48 28.80 -313,862 64,670,400
2015-10-29 2015-10-27 4 DMTX Dimension Therapeutics, Inc.
Series B Preferred Stock 		C - Conversion -5,692,874 0 -100.00
2015-10-29 2015-10-27 4 DMTX Dimension Therapeutics, Inc.
Series A Preferred Stock 		C - Conversion -9,500,000 0 -100.00
2015-10-29 2015-10-27 4 DMTX Dimension Therapeutics, Inc.
Common Stock 		P - Purchase 200,000 5,397,698 3.85 13.00 2,600,000 70,170,074
2015-10-29 2015-10-27 4 DMTX Dimension Therapeutics, Inc.
Common Stock 		C - Conversion 1,947,613 5,197,698 59.92
2015-10-29 2015-10-27 4 DMTX Dimension Therapeutics, Inc.
Common Stock 		C - Conversion 3,250,085 3,250,085
2015-10-22 2015-10-22 4 RLYP Relypsa Inc
Common Stock 		P - Purchase 310,700 7,900,000 4.09 12.92 4,014,244 102,068,000
2015-10-22 2015-10-22 4 RLYP Relypsa Inc
Common Stock 		P - Purchase 189,300 7,589,300 2.56 11.97 2,265,921 90,843,921
2015-10-13 2015-10-12 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share 		S - Sale -2,785 17,100 -14.01 5.98 -16,654 102,258
2015-10-13 2015-10-12 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share 		S - Sale -285,106 1,767,902 -13.89 5.98 -1,704,934 10,572,054
2015-10-09 2015-10-09 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share 		S - Sale -2,041 19,885 -9.31 7.03 -14,348 139,792
2015-10-09 2015-10-09 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share 		S - Sale -210,668 2,053,008 -9.31 7.03 -1,480,996 14,432,646
2015-10-09 2015-10-08 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share 		S - Sale -3,837 21,926 -14.89 7.24 -27,780 158,744
2015-10-09 2015-10-08 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share 		S - Sale -396,163 2,263,676 -14.89 7.24 -2,868,220 16,389,014
2015-10-09 2015-10-07 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share 		S - Sale -454 25,763 -1.73 7.36 -3,341 189,616
2015-10-09 2015-10-07 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share 		S - Sale -53,446 2,659,839 -1.97 7.36 -393,363 19,576,415
2015-10-06 2015-10-06 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share 		S - Sale -59 26,217 -0.22 7.80 -460 204,493
2015-10-06 2015-10-06 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share 		S - Sale -6,941 2,713,285 -0.26 7.80 -54,140 21,163,623
2015-10-06 2015-10-05 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share 		S - Sale -1,163 26,276 -4.24 8.19 -9,525 215,200
2015-10-06 2015-10-05 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share 		S - Sale -136,937 2,720,226 -4.79 8.19 -1,121,514 22,278,651
2015-10-06 2015-10-02 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share 		S - Sale -403 27,439 -1.45 10.34 -4,167 283,719
2015-10-06 2015-10-02 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share 		S - Sale -47,497 2,857,163 -1.64 10.34 -491,119 29,543,065
2015-10-01 2015-10-01 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share 		S - Sale -400 27,842 -1.42 10.34 -4,136 287,886
2015-10-01 2015-10-01 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share 		S - Sale -47,100 2,904,660 -1.60 10.34 -487,014 30,034,184
2015-10-01 2015-09-30 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share 		S - Sale -369 28,242 -1.29 10.17 -3,753 287,221
2015-10-01 2015-09-30 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share 		S - Sale -43,471 2,951,760 -1.45 10.17 -442,100 30,019,399
2015-10-01 2015-09-29 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share 		S - Sale -89 28,611 -0.31 10.08 -897 288,399
2015-10-01 2015-09-29 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share 		S - Sale -10,469 2,995,231 -0.35 10.08 -105,528 30,191,928
2015-09-28 2015-09-28 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share 		S - Sale -89 28,700 -0.31 10.30 -917 295,610
2015-09-28 2015-09-28 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share 		S - Sale -10,513 3,005,700 -0.35 10.30 -108,284 30,958,710
2015-09-28 2015-09-25 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share 		S - Sale -311 28,789 -1.07 11.07 -3,443 318,694
2015-09-28 2015-09-25 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share 		S - Sale -66,489 3,016,213 -2.16 11.07 -736,033 33,389,478
2015-09-28 2015-09-25 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share 		S - Sale -800 29,100 -2.68 10.07 -8,056 293,037
2015-09-28 2015-09-25 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share 		S - Sale -64,400 3,082,702 -2.05 10.07 -648,508 31,042,809
2015-09-28 2015-09-24 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share 		S - Sale -8,152 3,147,102 -0.26 11.00 -89,672 34,618,122
2015-09-28 2015-09-24 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share 		S - Sale -148 29,900 -0.49 11.00 -1,628 328,900
2015-09-28 2015-09-24 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share 		S - Sale -6 3,155,254 0.00 9.78 -59 30,858,384
2015-07-21 2015-07-17 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		A - Award 285 1,120,609 0.03
2015-07-21 2015-07-21 4 DNAI ProNAi Therapeutics Inc
Series D Preferred Stock 		C - Conversion -1,725,790 0 -100.00
2015-07-21 2015-07-21 4 DNAI ProNAi Therapeutics Inc
Common Stock 		P - Purchase 175,000 1,989,949 9.64 17.00 2,975,000 33,829,133
2015-07-21 2015-07-21 4 DNAI ProNAi Therapeutics Inc
Common Stock 		J - Other 89,159 1,814,949 5.17 5.22 464,964 9,464,959
2015-07-21 2015-07-21 4 DNAI ProNAi Therapeutics Inc
Common Stock 		C - Conversion 1,725,790 1,725,790
2015-07-08 2015-07-06 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 		P - Purchase 4,717 65,398 7.77 2.75 12,972 179,844
2015-07-08 2015-07-06 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 		P - Purchase 495,283 7,194,222 7.39 2.75 1,362,028 19,784,110
2015-06-30 2015-06-30 4 GKOS GLAUKOS Corp
Series D Convertible Preferred Stock Warrant (right to buy) 		M - Exercise -261 0 -100.00
2015-06-30 2015-06-30 4 GKOS GLAUKOS Corp
Series D Convertible Preferred Stock Warrant (right to buy) 		M - Exercise -27,346 0 -100.00
2015-06-30 2015-06-30 4 GKOS GLAUKOS Corp
Series F Convertible Preferred Stock 		C - Conversion -2,672 0 -100.00
2015-06-30 2015-06-30 4 GKOS GLAUKOS Corp
Series F Convertible Preferred Stock 		C - Conversion -280,531 0 -100.00
2015-06-30 2015-06-30 4 GKOS GLAUKOS Corp
Series E Convertible Preferred Stock 		C - Conversion -1,599 0 -100.00
2015-06-30 2015-06-30 4 GKOS GLAUKOS Corp
Series E Convertible Preferred Stock 		C - Conversion -167,898 0 -100.00
2015-06-30 2015-06-30 4 GKOS GLAUKOS Corp
Series D Convertible Preferred Stock 		C - Conversion -22,923 0 -100.00
2015-06-30 2015-06-30 4 GKOS GLAUKOS Corp
Series D Convertible Preferred Stock 		C - Conversion -2,406,441 0 -100.00
2015-06-30 2015-06-30 4 GKOS GLAUKOS Corp
Common Stock 		F - Taxes -111 27,344 -0.40 18.00 -1,998 492,192
2015-06-30 2015-06-30 4 GKOS GLAUKOS Corp
Common Stock 		M - Exercise 261 27,455 0.96
2015-06-30 2015-06-30 4 GKOS GLAUKOS Corp
Common Stock 		F - Taxes -11,623 2,870,593 -0.40 18.00 -209,214 51,670,674
2015-06-30 2015-06-30 4 GKOS GLAUKOS Corp
Common Stock 		M - Exercise 27,346 2,882,216 0.96
2015-06-30 2015-06-30 4 GKOS GLAUKOS Corp
Common Stock 		C - Conversion 27,194 27,194
2015-06-30 2015-06-30 4 GKOS GLAUKOS Corp
Common Stock 		C - Conversion 2,854,870 2,854,870
2015-06-29 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 		13,458,559
2015-06-29 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 		6,820,301
2015-06-29 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 		13,458,559
2015-06-29 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 		6,820,301
2015-06-29 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 		13,458,559
2015-06-29 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 		6,820,301
2015-06-29 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 		13,458,559
2015-06-29 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 		6,820,301
2015-05-20 2015-05-18 4 RLYP Relypsa Inc
Common Stock 		S - Sale -1,457,551 7,400,000 -16.46 34.13 -49,746,216 252,562,000
2015-03-30 2015-03-26 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -90 1,120,324 -0.01 294.82 -26,534 330,293,922
2015-03-30 2015-03-26 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -2,500 1,120,414 -0.22 293.85 -734,625 329,233,654
2015-03-30 2015-03-26 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -6,000 1,122,914 -0.53 292.13 -1,752,780 328,036,867
2015-03-30 2015-03-26 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -3,700 1,128,914 -0.33 291.12 -1,077,144 328,649,444
2015-03-30 2015-03-26 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -13,974 1,132,614 -1.22 290.02 -4,052,739 328,480,712
2015-03-30 2015-03-26 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -15,131 1,146,588 -1.30 289.07 -4,373,918 331,444,193
2015-03-30 2015-03-26 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -26,028 1,161,719 -2.19 288.11 -7,498,927 334,702,861
2015-03-30 2015-03-26 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -18,041 1,187,747 -1.50 287.16 -5,180,654 341,073,429
2015-03-30 2015-03-26 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -7,611 1,205,788 -0.63 286.24 -2,178,573 345,144,757
2015-03-30 2015-03-26 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -23,903 1,213,399 -1.93 285.18 -6,816,658 346,037,127
2015-03-30 2015-03-26 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -16,845 1,237,302 -1.34 284.20 -4,787,349 351,641,228
2015-03-30 2015-03-26 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -9,357 1,254,147 -0.74 282.87 -2,646,815 354,760,562
2015-03-30 2015-03-26 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -8,397 1,263,504 -0.66 282.13 -2,369,046 356,472,384
2015-03-30 2015-03-26 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -5,623 1,271,901 -0.44 281.11 -1,580,682 357,544,090
2015-03-25 2015-03-25 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -2,800 1,277,524 -0.22 270.23 -756,644 345,225,311
2015-03-25 2015-03-24 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -3,844 1,280,324 -0.30 275.56 -1,059,253 352,806,081
2015-03-25 2015-03-24 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -12,066 1,284,168 -0.93 275.00 -3,318,150 353,146,200
2015-03-25 2015-03-24 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -2,700 1,296,234 -0.21 273.19 -737,613 354,118,166
2015-03-25 2015-03-24 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -3,050 1,298,934 -0.23 272.13 -829,996 353,478,909
2015-03-25 2015-03-24 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -6,063 1,301,984 -0.46 271.15 -1,643,982 353,032,962
2015-03-25 2015-03-24 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -9,574 1,308,047 -0.73 270.13 -2,586,225 353,342,736
2015-03-25 2015-03-24 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -1,539 1,317,621 -0.12 269.10 -414,145 354,571,811
2015-03-25 2015-03-24 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -6,764 1,319,160 -0.51 268.13 -1,813,631 353,706,371
2015-03-25 2015-03-23 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -1,000 1,325,924 -0.08 288.60 -288,600 382,661,666
2015-03-25 2015-03-23 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -1,400 1,326,924 -0.11 286.04 -400,456 379,553,341
2015-03-25 2015-03-23 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -52 1,328,324 0.00 283.44 -14,739 376,500,155
2015-03-25 2015-03-23 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -1,548 1,328,376 -0.12 283.29 -438,533 376,315,637
2015-03-25 2015-03-23 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -3,500 1,329,924 -0.26 282.00 -987,000 375,038,568
2015-03-25 2015-03-23 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -6,306 1,333,424 -0.47 281.01 -1,772,049 374,705,478
2015-03-25 2015-03-23 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -9,465 1,339,730 -0.70 280.00 -2,650,200 375,124,400
2015-03-25 2015-03-23 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -3,668 1,349,195 -0.27 279.00 -1,023,372 376,425,405
2015-03-25 2015-03-23 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -14,152 1,352,863 -1.04 278.00 -3,934,256 376,095,914
2015-03-25 2015-03-23 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -8,195 1,367,015 -0.60 276.96 -2,269,687 378,608,474
2015-03-25 2015-03-23 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -37,666 1,375,210 -2.67 275.95 -10,393,933 379,489,200
2015-03-25 2015-03-23 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -3,579 1,412,876 -0.25 274.86 -983,724 388,343,097
2015-03-25 2015-03-23 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -11,869 1,416,455 -0.83 273.89 -3,250,800 387,952,860
2015-03-25 2015-03-23 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -8,638 1,428,324 -0.60 272.79 -2,356,360 389,632,504
2015-03-25 2015-03-23 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -7,764 1,436,962 -0.54 271.70 -2,109,479 390,422,575
2015-03-25 2015-03-23 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -40,598 1,444,726 -2.73 270.70 -10,989,879 391,087,328
2015-02-05 2015-02-03 4 MRTX Mirati Therapeutics, Inc.
Common Stock, par value $0.001 per share 		P - Purchase 100,000 1,267,000 8.57 20.00 2,000,000 25,340,000
2014-10-28 3 SIEN Sientra, Inc.
Common Stock 		6,340,568
2014-10-28 3 SIEN Sientra, Inc.
Common Stock 		3,215,356
2014-10-28 3 SIEN Sientra, Inc.
Common Stock 		6,340,568
2014-10-28 3 SIEN Sientra, Inc.
Common Stock 		3,215,356
2014-10-28 3 SIEN Sientra, Inc.
Common Stock 		6,340,568
2014-10-28 3 SIEN Sientra, Inc.
Common Stock 		3,215,356
2014-10-28 3 SIEN Sientra, Inc.
Common Stock 		6,340,568
2014-10-28 3 SIEN Sientra, Inc.
Common Stock 		3,215,356
2014-09-18 2014-09-17 4 RLYP Relypsa Inc
Common Stock 		S - Sale -49,000 8,857,551 -0.55 25.07 -1,228,430 222,058,804
2014-09-18 2014-09-16 4 RLYP Relypsa Inc
Common Stock 		S - Sale -2,600 8,906,551 -0.03 26.06 -67,756 232,104,719
2014-09-18 2014-09-16 4 RLYP Relypsa Inc
Common Stock 		S - Sale -42,400 8,909,151 -0.47 25.45 -1,079,080 226,737,893
2014-08-27 2014-08-26 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -400 1,485,324 -0.03 302.34 -120,936 449,072,858
2014-08-27 2014-08-26 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -5,400 1,485,724 -0.36 301.36 -1,627,344 447,737,785
2014-08-27 2014-08-26 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -45,058 1,491,124 -2.93 300.11 -13,522,356 447,501,224
2014-08-27 2014-08-26 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -10,400 1,536,182 -0.67 299.13 -3,110,952 459,518,122
2014-08-27 2014-08-25 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -1,990 1,546,582 -0.13 297.26 -591,547 459,736,965
2014-08-27 2014-08-25 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -10,010 1,548,572 -0.64 296.59 -2,968,866 459,290,969
2014-08-27 2014-08-25 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -25,442 1,558,582 -1.61 295.52 -7,518,620 460,592,153
2014-08-27 2014-08-25 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -12,558 1,584,024 -0.79 294.67 -3,700,466 466,764,352
2014-08-19 2014-08-18 4 OTIC Otonomy, Inc.
Series D Preferred Stock 		C - Conversion -378,039 0 -100.00
2014-08-19 2014-08-18 4 OTIC Otonomy, Inc.
Series C Preferred Stock 		C - Conversion -1,706,484 0 -100.00
2014-08-19 2014-08-18 4 OTIC Otonomy, Inc.
Common Stock 		P - Purchase 171,875 2,256,398 8.25 16.00 2,750,000 36,102,368
2014-08-19 2014-08-18 4 OTIC Otonomy, Inc.
Common Stock 		C - Conversion 2,084,523 2,084,523
2014-08-19 2014-08-15 4 RLYP Relypsa Inc
Common Stock 		S - Sale -990,000 8,951,551 -9.96 26.35 -26,086,500 235,873,369
2014-08-18 2014-08-14 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -350 1,596,582 -0.02 308.13 -107,844 491,948,425
2014-08-18 2014-08-14 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -14,640 1,596,932 -0.91 307.06 -4,495,314 490,349,149
2014-08-18 2014-08-14 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -525 1,611,572 -0.03 306.23 -160,772 493,516,528
2014-08-18 2014-08-14 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -1,732 1,612,097 -0.11 305.14 -528,501 491,913,666
2014-08-18 2014-08-14 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -1,193 1,613,829 -0.07 303.77 -362,394 490,227,994
2014-08-18 2014-08-14 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -1,100 1,615,022 -0.07 302.55 -332,806 488,626,521
2014-08-18 2014-08-14 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -1,710 1,616,122 -0.11 301.42 -515,426 487,129,877
2014-08-18 2014-08-14 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -3,985 1,617,832 -0.25 300.21 -1,196,329 485,686,109
2014-08-18 2014-08-14 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -100 1,621,817 -0.01 298.61 -29,861 484,290,774
2014-08-18 2014-08-14 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -9,985 1,621,917 -0.61 297.76 -2,973,134 482,942,006
2014-08-18 2014-08-14 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -6,192 1,631,902 -0.38 296.86 -1,838,139 484,441,532
2014-08-18 2014-08-14 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -7,062 1,638,094 -0.43 296.21 -2,091,814 485,214,909
2014-08-18 2014-08-14 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -3,254 1,645,156 -0.20 294.96 -959,800 485,255,214
2014-08-18 2014-08-14 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -4,468 1,648,410 -0.27 293.85 -1,312,908 484,380,333
2014-08-18 2014-08-14 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -3,704 1,652,878 -0.22 292.70 -1,084,165 483,799,043
2014-08-11 2014-08-09 4 ICPT INTERCEPT PHARMACEUTICALS INC
Restricted Stock Units 		M - Exercise -324 0 -100.00
2014-08-11 2014-08-09 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		M - Exercise 324 1,656,582 0.02
2014-08-06 2014-08-06 4 LOXO Loxo Oncology, Inc.
Series B Convertible Preferred Stock 		C - Conversion -337,973 0 -100.00
2014-08-06 2014-08-06 4 LOXO Loxo Oncology, Inc.
Series A Convertible Preferred Stock 		C - Conversion -1,562,499 0 -100.00
2014-08-06 2014-08-06 4 LOXO Loxo Oncology, Inc.
Common Stock 		P - Purchase 275,385 2,175,857 14.49 13.00 3,580,005 28,286,141
2014-08-06 2014-08-06 4 LOXO Loxo Oncology, Inc.
Common Stock 		C - Conversion 337,973 1,900,472 21.63
2014-08-06 2014-08-06 4 LOXO Loxo Oncology, Inc.
Common Stock 		C - Conversion 1,562,499 1,562,499
2014-07-24 2014-07-22 4 ROKA Roka BioScience, Inc.
Series E Convertible Preferred Stock 		C - Conversion -56,490 0 -100.00
2014-07-24 2014-07-22 4 ROKA Roka BioScience, Inc.
Series E Convertible Preferred Stock 		C - Conversion -5,931,402 0 -100.00
2014-07-24 2014-07-22 4 ROKA Roka BioScience, Inc.
Series D Convertible Preferred Stock 		C - Conversion -80,715 0 -100.00
2014-07-24 2014-07-22 4 ROKA Roka BioScience, Inc.
Series D Convertible Preferred Stock 		C - Conversion -8,475,069 0 -100.00
2014-07-24 2014-07-22 4 ROKA Roka BioScience, Inc.
Series C Convertible Preferred Stock 		C - Conversion -38,021 0 -100.00
2014-07-24 2014-07-22 4 ROKA Roka BioScience, Inc.
Series C Convertible Preferred Stock 		C - Conversion -3,992,203 0 -100.00
2014-07-24 2014-07-22 4 ROKA Roka BioScience, Inc.
Series B Convertible Preferred Stock 		C - Conversion -116,981 0 -100.00
2014-07-24 2014-07-22 4 ROKA Roka BioScience, Inc.
Series B Convertible Preferred Stock 		C - Conversion -12,238,019 0 -100.00
2014-07-24 2014-07-22 4 ROKA Roka BioScience, Inc.
Common Stock, $0.001 par value per share 		P - Purchase 3,616 30,378 13.51 12.00 43,392 364,536
2014-07-24 2014-07-22 4 ROKA Roka BioScience, Inc.
Common Stock, $0.001 par value per share 		P - Purchase 379,717 3,190,051 13.51 12.00 4,556,604 38,280,612
2014-07-24 2014-07-22 4 ROKA Roka BioScience, Inc.
Common Stock, $0.001 par value per share 		C - Conversion 5,116 26,762 23.63
2014-07-24 2014-07-22 4 ROKA Roka BioScience, Inc.
Common Stock, $0.001 par value per share 		C - Conversion 537,264 2,810,334 23.64
2014-07-24 2014-07-22 4 ROKA Roka BioScience, Inc.
Common Stock, $0.001 par value per share 		C - Conversion 7,563 21,646 53.70
2014-07-24 2014-07-22 4 ROKA Roka BioScience, Inc.
Common Stock, $0.001 par value per share 		C - Conversion 794,178 2,273,070 53.70
2014-07-24 2014-07-22 4 ROKA Roka BioScience, Inc.
Common Stock, $0.001 par value per share 		C - Conversion 3,443 14,083 32.36
2014-07-24 2014-07-22 4 ROKA Roka BioScience, Inc.
Common Stock, $0.001 par value per share 		C - Conversion 361,612 1,478,892 32.37
2014-07-24 2014-07-22 4 ROKA Roka BioScience, Inc.
Common Stock, $0.001 par value per share 		C - Conversion 10,596 10,640 24,081.82
2014-07-24 2014-07-22 4 ROKA Roka BioScience, Inc.
Common Stock, $0.001 par value per share 		C - Conversion 1,112,592 1,117,280 23,732.76
2014-07-16 3 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share 		9,420
2014-07-16 3 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share 		4,776
2014-07-16 3 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share 		9,420
2014-07-16 3 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share 		4,776
2014-07-16 3 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share 		9,420
2014-07-16 3 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share 		4,776
2014-07-16 3 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share 		9,420
2014-07-16 3 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share 		4,776
2014-07-01 2014-07-01 4 MRTX Mirati Therapeutics, Inc.
Common Stock, par value $0.001 per share 		S - Sale -5,000 1,167,000 -0.43 20.04 -100,200 23,386,680
2014-07-01 2014-06-30 4 MRTX Mirati Therapeutics, Inc.
Common Stock, par value $0.001 per share 		S - Sale -4,717 1,172,000 -0.40 21.11 -99,576 24,740,920
2014-07-01 2014-06-30 4 MRTX Mirati Therapeutics, Inc.
Common Stock, par value $0.001 per share 		S - Sale -9,283 1,176,717 -0.78 20.33 -188,723 23,922,657
2014-07-01 2014-06-27 4 MRTX Mirati Therapeutics, Inc.
Common Stock, par value $0.001 per share 		S - Sale -9,212 1,186,000 -0.77 23.09 -212,705 27,384,740
2014-07-01 2014-06-27 4 MRTX Mirati Therapeutics, Inc.
Common Stock, par value $0.001 per share 		S - Sale -79,120 1,195,212 -6.21 21.79 -1,724,025 26,043,669
2014-05-09 2014-05-09 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		M - Exercise 325 1,656,258 0.02
2014-05-09 2014-05-07 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		M - Exercise 1,330 1,655,933 0.08
2014-05-09 2013-05-09 4 ICPT INTERCEPT PHARMACEUTICALS INC
Restricted Stock Units 		M - Exercise -325 324 -50.08
2014-05-09 2013-05-07 4 ICPT INTERCEPT PHARMACEUTICALS INC
Restricted Stock Units 		M - Exercise -1,330 0 -100.00
2014-04-11 2014-04-09 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -81,305 1,654,603 -4.68 320.00 -26,017,600 529,472,960
2014-02-11 2014-02-09 4 ICPT INTERCEPT PHARMACEUTICALS INC
Restricted Stock Units 		M - Exercise -324 649 -33.30
2014-02-11 2014-02-09 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		M - Exercise 324 1,735,908 0.02
2013-11-20 2013-11-20 4 RLYP Relypsa Inc
Warrant to Purchase Common Stock 		M - Exercise -327,133 0 -100.00
2013-11-20 2013-11-20 4 RLYP Relypsa Inc
Warrant to Purchase Common Stock 		J - Other 327,133 327,133
2013-11-20 2013-11-20 4 RLYP Relypsa Inc
Warrant to Purchase Preferred Stock 		J - Other -327,133 0 -100.00
2013-11-20 2013-11-20 4 RLYP Relypsa Inc
Warrant to Purchase Common Stock 		M - Exercise -1,417,578 0 -100.00
2013-11-20 2013-11-20 4 RLYP Relypsa Inc
Warrant to Purchase Common Stock 		J - Other 1,417,578 1,417,578
2013-11-20 2013-11-20 4 RLYP Relypsa Inc
Warrant to Purchase Preferred Stock 		J - Other -1,417,578 0 -100.00
2013-11-20 2013-11-20 4 RLYP Relypsa Inc
Series C-2 Preferred Stock 		C - Conversion -693,991 0 -100.00
2013-11-20 2013-11-20 4 RLYP Relypsa Inc
Series C-1 Preferred Stock 		C - Conversion -3,007,297 0 -100.00
2013-11-20 2013-11-20 4 RLYP Relypsa Inc
Series B-2 Preferred Stock 		C - Conversion -1,905,702 0 -100.00
2013-11-20 2013-11-20 4 RLYP Relypsa Inc
Series B-1 Preferred Stock 		C - Conversion -1,295,845 0 -100.00
2013-11-20 2013-11-20 4 RLYP Relypsa Inc
Common Stock 		P - Purchase 712,192 9,941,551 7.72 11.00 7,834,112 109,357,061
2013-11-20 2013-11-20 4 RLYP Relypsa Inc
Common Stock 		F - Taxes -5,116 9,229,359 -0.06 11.00 -56,276 101,522,949
2013-11-20 2013-11-20 4 RLYP Relypsa Inc
Common Stock 		M - Exercise 327,133 9,234,475 3.67 0.17 55,613 1,569,861
2013-11-20 2013-11-20 4 RLYP Relypsa Inc
Common Stock 		F - Taxes -22,166 8,907,342 -0.25 11.00 -243,826 97,980,762
2013-11-20 2013-11-20 4 RLYP Relypsa Inc
Common Stock 		M - Exercise 1,417,578 8,929,508 18.87 0.17 240,988 1,518,016
2013-11-20 2013-11-20 4 RLYP Relypsa Inc
Common Stock 		C - Conversion 693,991 7,511,930 10.18
2013-11-20 2013-11-20 4 RLYP Relypsa Inc
Common Stock 		C - Conversion 3,007,297 6,817,939 78.92
2013-11-20 2013-11-20 4 RLYP Relypsa Inc
Common Stock 		C - Conversion 1,905,702 3,810,642 100.04
2013-11-20 2013-11-20 4 RLYP Relypsa Inc
Common Stock 		C - Conversion 1,904,940 1,904,940
2013-11-12 2013-11-07 4 RBM RESPONSE BIOMEDICAL CORP
Warrant 		P - Purchase 151,632 151,632
2013-11-12 2013-11-07 4 RBM RESPONSE BIOMEDICAL CORP
Warrant 		P - Purchase 2,408 2,408
2013-11-12 2013-11-07 4 RBM RESPONSE BIOMEDICAL CORP
Warrant 		P - Purchase 254,122 254,122
2013-11-12 2013-11-07 4 RBM RESPONSE BIOMEDICAL CORP
Common Stock 		P - Purchase 303,265 1,818,677 20.01 2.45 742,999 4,455,759
2013-11-12 2013-11-07 4 RBM RESPONSE BIOMEDICAL CORP
Common Stock 		P - Purchase 4,816 28,997 19.92 2.45 11,799 71,043
2013-11-12 2013-11-07 4 RBM RESPONSE BIOMEDICAL CORP
Common Stock 		P - Purchase 508,244 3,047,927 20.01 2.45 1,245,198 7,467,421
2013-11-12 2013-11-09 4 ICPT INTERCEPT PHARMACEUTICALS INC
Restricted Stock Units 		M - Exercise -325 973 -25.04
2013-11-12 2013-11-09 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		M - Exercise 325 1,735,584 0.02
2013-10-31 2013-10-29 4 MRTX Mirati Therapeutics, Inc.
Common Stock, par value $0.001 per share 		P - Purchase 125,000 1,274,332 10.88 17.50 2,187,500 22,300,810
2013-10-23 2013-10-21 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -40,088 1,735,259 -2.26 62.50 -2,505,500 108,453,688
2013-10-17 2013-10-15 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		S - Sale -376,585 1,775,347 -17.50 62.50 -23,536,562 110,959,188
2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Series F Convertible Preferred 		C - Conversion -14,574 0 -100.00
2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Series F Convertible Preferred 		C - Conversion -38,924 0 -100.00
2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Series E Convertible Preferred 		C - Conversion -8,466 0 -100.00
2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Series E Convertible Preferred 		C - Conversion -22,612 0 -100.00
2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Series E Convertible Preferred Stock 		C - Conversion -31,113 0 -100.00
2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Series E Convertible Preferred 		C - Conversion -83,097 0 -100.00
2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Series D Convertible Preferred Stock 		C - Conversion -8,777 0 -100.00
2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Series D Convertible Preferred 		C - Conversion -23,442 0 -100.00
2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Series C Convertible Preferred Stock 		C - Conversion -65,680 0 -100.00
2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Series C Convertible Preferred 		C - Conversion -175,419 0 -100.00
2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Series B Convertible Preferred Stock 		C - Conversion -422,101 0 -100.00
2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Series B Convertible Preferred Stock 		C - Conversion -1,127,346 0 -100.00
2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Common Stock 		C - Conversion 14,574 576,889 2.59
2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Common Stock 		C - Conversion 38,924 1,540,759 2.59
2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Common Stock 		C - Conversion 13,431 562,315 2.45
2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Common Stock 		C - Conversion 35,873 1,501,835 2.45
2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Common Stock 		C - Conversion 50,145 548,884 10.05
2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Common Stock 		C - Conversion 133,930 1,465,962 10.05
2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Common Stock 		C - Conversion 8,777 498,739 1.79
2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Common Stock 		C - Conversion 23,442 1,332,032 1.79
2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Common Stock 		C - Conversion 65,680 489,962 15.48
2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Common Stock 		C - Conversion 175,419 1,308,590 15.48
2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Common Stock 		C - Conversion 422,101 424,282 19,353.55
2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Common Stock 		C - Conversion 1,127,346 1,133,171 19,353.58
2013-09-18 3 XLRN ACCELERON PHARMA INC
Common Stock 		5,825
2013-09-18 3 XLRN ACCELERON PHARMA INC
Common Stock 		2,181
2013-08-13 2013-08-09 4 ICPT INTERCEPT PHARMACEUTICALS INC
Restricted Stock Units 		M - Exercise -325 1,298 -20.02
2013-08-13 2013-08-09 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		M - Exercise 325 2,151,932 0.02
2013-07-16 3 MRTX Mirati Therapeutics, Inc.
Common Stock 		1,149,332
2013-05-24 2013-05-23 4 AMBI AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share 		P - Purchase 120 14,067 0.86 6.99 839 98,318
2013-05-24 2013-05-23 4 AMBI AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share 		P - Purchase 12,380 1,476,702 0.85 6.99 86,528 10,321,113
2013-05-24 2013-05-22 4 AMBI AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share 		P - Purchase 200 13,947 1.45 6.86 1,372 95,690
2013-05-24 2013-05-22 4 AMBI AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share 		P - Purchase 21,100 1,464,322 1.46 6.86 144,767 10,046,713
2013-05-22 2013-05-21 4 AMBI AMBIT BIOSCIENCES CORP
Series D Convertible Preferred Stock 		C - Conversion -18,795 0 -100.00
2013-05-22 2013-05-21 4 AMBI AMBIT BIOSCIENCES CORP
Series D Convertible Preferred Stock 		C - Conversion -1,973,439 0 -100.00
2013-05-22 2013-05-21 4 AMBI AMBIT BIOSCIENCES CORP
Series D-2 Convertible Preferred Stock 		C - Conversion -50,256 0 -100.00
2013-05-22 2013-05-21 4 AMBI AMBIT BIOSCIENCES CORP
Series D-2 Convertible Preferred Stock 		C - Conversion -5,276,702 0 -100.00
2013-05-22 2013-05-21 4 AMBI AMBIT BIOSCIENCES CORP
Series E Convertible Preferred Stock 		C - Conversion -83,959 0 -100.00
2013-05-22 2013-05-21 4 AMBI AMBIT BIOSCIENCES CORP
Series E Convertible Preferred Stock 		C - Conversion -8,815,565 0 -100.00
2013-05-22 2013-05-21 4 AMBI AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share 		P - Purchase 80 13,747 0.59 6.90 552 94,813
2013-05-22 2013-05-21 4 AMBI AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share 		P - Purchase 8,020 1,443,222 0.56 6.90 55,314 9,953,902
2013-05-22 2013-05-21 4 AMBI AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share 		P - Purchase 590 13,667 4.51 8.00 4,720 109,336
2013-05-22 2013-05-21 4 AMBI AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share 		P - Purchase 61,910 1,435,202 4.51 8.00 495,280 11,481,616
2013-05-22 2013-05-21 4 AMBI AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share 		P - Purchase 5,653 13,077 76.14 8.00 45,224 104,616
2013-05-22 2013-05-21 4 AMBI AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share 		P - Purchase 593,618 1,373,292 76.14 8.00 4,748,944 10,986,336
2013-05-22 2013-05-21 4 AMBI AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share 		C - Conversion 1,730 7,424 30.38
2013-05-22 2013-05-21 4 AMBI AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share 		C - Conversion 181,689 779,674 30.38
2013-05-22 2013-05-21 4 AMBI AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share 		C - Conversion 2,094 5,694 58.17
2013-05-22 2013-05-21 4 AMBI AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share 		C - Conversion 219,863 597,985 58.15
2013-05-22 2013-05-21 4 AMBI AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share 		C - Conversion 3,498 3,600 3,429.41
2013-05-22 2013-05-21 4 AMBI AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share 		C - Conversion 367,315 378,122 3,398.86
2013-05-22 2013-05-20 4 AMBI AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share 		P - Purchase 100 102 5,000.00 6.78 678 691
2013-05-22 2013-05-20 4 AMBI AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share 		P - Purchase 10,500 10,807 3,420.20 6.78 71,162 73,242
2013-05-15 3 AMBI AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share 		307
2013-05-15 3 AMBI AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share 		2
2013-05-13 2013-05-09 4 ICPT INTERCEPT PHARMACEUTICALS INC
Restricted Stock Units 		M - Exercise -324 1,623 -16.64
2013-05-13 2013-05-09 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		M - Exercise 324 2,151,607 0.02
2013-04-15 2013-04-09 4 ICPT INTERCEPT PHARMACEUTICALS INC
Restricted Stock Units 		M - Exercise -649 1,947 -25.00
2013-04-15 2013-04-09 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		M - Exercise 649 2,151,283 0.03
2013-02-14 2013-02-13 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock 		S - Sale -41,100 817,000 -4.79 7.58 -311,361 6,189,347
2013-02-14 2013-02-13 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock 		S - Sale -108,900 2,183,000 -4.75 7.58 -824,994 16,537,753
2013-02-14 2013-02-12 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock 		S - Sale -41,483 858,100 -4.61 7.52 -312,027 6,454,457
2013-02-14 2013-02-12 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock 		S - Sale -110,700 2,291,900 -4.61 7.52 -832,663 17,239,213
2013-02-01 2013-01-30 4 ANTH Anthera Pharmaceuticals Inc
Common Stock 		P - Purchase 5,700,000 7,462,000 323.50 0.66 3,762,000 4,924,920
2013-01-29 2013-01-25 4 ANTH Anthera Pharmaceuticals Inc
Common Stock 		P - Purchase 1,762,000 1,762,000 0.65 1,142,481 1,142,481
2012-12-19 2012-12-18 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock 		S - Sale -100,000 0 -100.00 7.08 -707,670
2012-12-19 2012-12-17 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock 		S - Sale -197,815 100,000 -66.42 6.85 -1,354,617 684,790
2012-10-16 2012-10-16 4 ICPT INTERCEPT PHARMACEUTICALS INC
Series C Preferred Stock 		C - Conversion -10,500,000 0 -100.00
2012-10-16 2012-10-16 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		P - Purchase 333,334 2,150,634 18.34 15.00 5,000,010 32,259,510
2012-10-16 2012-10-16 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share 		C - Conversion 1,817,300 1,817,300
2012-09-05 2012-09-04 4 AMRN AMARIN CORP PLC\UK
Ordinary Shares 		S - Sale X -2,244 5,700 -28.25 14.43 -32,388 82,268
2012-09-05 2012-09-04 4 AMRN AMARIN CORP PLC\UK
Ordinary Shares 		S - Sale X -231,456 594,300 -28.03 14.43 -3,340,604 8,577,532
2012-07-30 2012-07-27 4 AMRN AMARIN CORP PLC\UK
Ordinary Shares 		S - Sale X -3,456 7,944 -30.32 14.61 -50,483 116,041
2012-07-30 2012-07-27 4 AMRN AMARIN CORP PLC\UK
Ordinary Shares 		S - Sale X -362,844 825,756 -30.53 14.61 -5,300,207 12,062,148
2012-07-13 2012-07-13 4 GNOM COMPLETE GENOMICS INC
Common Stock 		S - Sale -4,500 27,859 -13.91 2.51 -11,298 69,943
2012-07-13 2012-07-13 4 GNOM COMPLETE GENOMICS INC
Common Stock 		S - Sale -474,800 2,922,141 -13.98 2.51 -1,192,033 7,336,327
2012-07-13 2012-07-12 4 GNOM COMPLETE GENOMICS INC
Common Stock 		S - Sale -2,076 32,359 -6.03 2.85 -5,916 92,210
2012-07-13 2012-07-12 4 GNOM COMPLETE GENOMICS INC
Common Stock 		S - Sale -218,624 3,396,941 -6.05 2.85 -622,991 9,679,923
2012-07-13 2012-07-11 4 GNOM COMPLETE GENOMICS INC
Common Stock 		S - Sale -4,792 34,435 -12.22 2.90 -13,891 99,820
2012-07-13 2012-07-11 4 GNOM COMPLETE GENOMICS INC
Common Stock 		S - Sale -503,144 3,615,565 -12.22 2.90 -1,458,514 10,480,800
2012-07-03 2012-06-29 4 ANTH Anthera Pharmaceuticals Inc
Common Stock 		S - Sale -1,283,300 0 -100.00 0.73 -942,071
2012-06-19 2012-06-19 4 AMRN AMARIN CORP PLC\UK
Ordinary Shares 		S - Sale -5,900 11,400 -34.10 12.91 -76,185 147,205
2012-06-19 2012-06-19 4 AMRN AMARIN CORP PLC\UK
Ordinary Shares 		S - Sale -611,200 1,188,600 -33.96 12.91 -7,892,242 15,348,035
2012-05-08 2012-05-04 4 SUPN SUPERNUS PHARMACEUTICALS INC
Series A Convertible Preferred Stock 		C - Conversion -827,627 0 -100.00
2012-05-08 2012-05-04 4 SUPN SUPERNUS PHARMACEUTICALS INC
Series A Convertible Preferred Stock 		C - Conversion -2,498,842 0 -100.00
2012-05-08 2012-05-04 4 SUPN SUPERNUS PHARMACEUTICALS INC
Series A Convertible Preferred Stock 		C - Conversion -6,673,891 0 -100.00
2012-05-08 2012-05-04 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock 		P - Purchase 90,999 297,815 44.00 5.00 454,995 1,489,075
2012-05-08 2012-05-04 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock 		P - Purchase 274,873 899,583 44.00 5.00 1,374,365 4,497,915
2012-05-08 2012-05-04 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock 		P - Purchase 734,128 2,402,600 44.00 5.00 3,670,640 12,013,000
2012-05-08 2012-05-04 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock 		C - Conversion 206,816 206,816
2012-05-08 2012-05-04 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock 		C - Conversion 624,710 624,710
2012-05-08 2012-05-04 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock 		C - Conversion 1,668,472 1,668,472
2012-03-22 2012-03-22 4 ANTH Anthera Pharmaceuticals Inc
Common Stock 		S - Sale -1,306,700 1,283,300 -50.45 2.40 -3,140,131 3,083,898
2012-03-22 2012-03-21 4 ANTH Anthera Pharmaceuticals Inc
Common Stock 		S - Sale -125,000 2,590,000 -4.60 2.87 -358,312 7,424,235
2012-03-22 2012-03-20 4 ANTH Anthera Pharmaceuticals Inc
Common Stock 		S - Sale -116,800 2,715,000 -4.12 2.90 -338,638 7,871,600
2012-03-13 2012-03-12 4 PCRX Pacira Pharmaceuticals, Inc.
Common Stock 		S - Sale -700 2,446,000 -0.03 11.03 -7,722 26,983,783
2012-03-13 2012-03-12 4 PCRX Pacira Pharmaceuticals, Inc.
Common Stock 		S - Sale -62,400 2,446,700 -2.49 11.03 -688,384 26,991,505
2012-03-13 2012-03-09 4 PCRX Pacira Pharmaceuticals, Inc.
Common Stock 		S - Sale -300 2,509,100 -0.01 11.25 -3,374 28,216,335
2012-03-13 2012-03-09 4 PCRX Pacira Pharmaceuticals, Inc.
Common Stock 		S - Sale -36,700 2,509,400 -1.44 11.25 -412,714 28,219,709
2012-02-29 2012-02-29 4 PCRX Pacira Pharmaceuticals, Inc.
Common Stock 		S - Sale -3,000 2,546,100 -0.12 10.86 -32,584 27,654,211
2012-02-29 2012-02-28 4 PCRX Pacira Pharmaceuticals, Inc.
Common Stock 		S - Sale -100 2,549,100 0.00 11.12 -1,112 28,347,012
2012-02-29 2012-02-28 4 PCRX Pacira Pharmaceuticals, Inc.
Common Stock 		S - Sale -10,000 2,549,200 -0.39 11.12 -111,204 28,348,124
2012-02-29 2012-02-27 4 PCRX Pacira Pharmaceuticals, Inc.
Common Stock 		S - Sale -300 2,559,200 -0.01 11.05 -3,314 28,271,994
2012-02-29 2012-02-27 4 PCRX Pacira Pharmaceuticals, Inc.
Common Stock 		S - Sale -28,700 2,559,500 -1.11 11.05 -317,055 28,275,308
2012-02-15 2012-02-13 4 CCXI ChemoCentryx, Inc.
Series C Preferred Stock 		C - Conversion -242,674 0 -100.00
2012-02-15 2012-02-13 4 CCXI ChemoCentryx, Inc.
Series B Preferred Stock 		C - Conversion -1,574,345 0 -100.00
2012-02-15 2012-02-13 4 CCXI ChemoCentryx, Inc.
Series C Preferred Stock 		C - Conversion -514,354 0 -100.00
2012-02-15 2012-02-13 4 CCXI ChemoCentryx, Inc.
Series B Preferred Stock 		C - Conversion -3,888,423 0 -100.00
2012-02-15 2012-02-13 4 CCXI ChemoCentryx, Inc.
Series C Preferred Stock 		C - Conversion -10,706 0 -100.00
2012-02-15 2012-02-13 4 CCXI ChemoCentryx, Inc.
Series B Preferred Stock 		C - Conversion -78,928 0 -100.00
2012-02-15 2012-02-13 4 CCXI ChemoCentryx, Inc.
Common Stock 		C - Conversion 908,509 908,509
2012-02-15 2012-02-13 4 CCXI ChemoCentryx, Inc.
Common Stock 		C - Conversion 2,201,388 2,201,388
2012-02-15 2012-02-13 4 CCXI ChemoCentryx, Inc.
Common Stock 		C - Conversion 44,817 44,817
2012-02-03 2012-02-03 4 PCRX Pacira Pharmaceuticals, Inc.
Common Stock 		S - Sale -500 2,588,200 -0.02 10.79 -5,395 27,927,713
2012-02-03 2012-02-03 4 PCRX Pacira Pharmaceuticals, Inc.
Common Stock 		S - Sale -49,500 2,588,700 -1.88 10.79 -534,125 27,933,108
2012-02-03 2012-02-02 4 PCRX Pacira Pharmaceuticals, Inc.
Common Stock 		S - Sale -200 2,638,200 -0.01 10.85 -2,171 28,637,133
2012-02-03 2012-02-02 4 PCRX Pacira Pharmaceuticals, Inc.
Common Stock 		S - Sale -23,100 2,638,400 -0.87 10.85 -250,746 28,639,304
2012-02-03 2012-02-01 4 PCRX Pacira Pharmaceuticals, Inc.
Common Stock 		S - Sale -700 2,661,500 -0.03 11.01 -7,704 29,291,937
2012-02-03 2012-02-01 4 PCRX Pacira Pharmaceuticals, Inc.
Common Stock 		S - Sale -69,300 2,662,200 -2.54 11.01 -762,702 29,299,641
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)